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Abstract: The TS/A cell line was established in 1983 from a spontaneous mammary tumor arisen in 
an inbred BALB/c female mouse. Its features (heterogeneity, low immunogenicity and metastatic 
ability) rendered the TS/A cell line suitable as a preclinical model for studies on tumor–host 
interactions and for gene therapy approaches. The integrated biological profile of TS/A resulting 
from the review of the literature could be a path towards the description of a precision experimental 
model of mammary cancer. 
Keywords: TS/A; murine mammary cancer; preclinical models; gene therapy; metastases; 
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1. Introduction 
Precision medicine in clinics is an evolving concept which goes beyond mere genomic medicine 
and means matching individual patients with medicine [1]. According to these premises, in an 
experimental environment a precision cancer model should mean matching the appropriate 
preclinical model with target biology study [2]. Preclinical models of mammary cancer of increasing 
complexity have been proposed, including transplantable murine tumors, gene-driven mammary 
carcinogenic models, human cell lines grown in vitro or in vivo as xenografts and patient-derived 
xenografts and organoids (see Section 6 for a comparative discussion) [3,4]. Each model remains an 
approximation [2], with advantages and disadvantages depending on the specific aim of the study. 
The main advantage of transplantable murine mammary tumors consists of allowing mechanistic 
studies on tumor–host interactions, like those focusing on the role of microenvironment, the 
metastatic process and the immune response. A deep knowledge of a preclinical model, where 
literature studies are collected and retrospectively examined as a whole, like an individual patient’s 
medical record, can help in a better design of experimental approaches. The aim of this review is the 
biological profiling of a popular model of murine mammary cancer (TS/A) for a better understanding 
and modeling of a complex pathology like human breast cancer [5]. 
2. The Dawn of Murine Models for Tumor–Host Interactions 
At the beginning of the 1980s, metastases and tumor–host interaction studies mostly took 
advantage of a few tumor cell lines, established and subcultured for many years, such as 3LL Lewis 
lung carcinoma and B16 murine spontaneous melanoma [6]. Through the intravenous injection of 
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B16 cells, metastatic deposits to lungs and other organs could be easily obtained, allowing for 
important advancements in understanding post-intravasation late phases of the metastatic process. 
However, the B16 parental cell line was almost incapable of disseminating from a locally-growing 
tumor, and therefore it did not adequately model the invasion and intravasation phases. Moreover, 
the non-epithelial origin of B16 melanoma impeded inferences about the behavior of epithelial 
tumors. At the same time, some rodent cell lines were already being used as models for mammary 
cancer, but most of them were either carcinogen- or virus-induced [7,8]. These models did not 
undergo a long natural history in the host, in which they arose, and generally had a high 
immunogenicity due to the expression of strong tumor-associated antigens. Likely due to these 
features, they generally gave too optimistic results when used to study antitumor immune responses 
or immunotherapeutic approaches [9]. 
In this landscape, in 1983 we described a new cell line, TS/A, derived from a mammary tumor 
spontaneously arisen in a 20 month-old BALB/c inbred mouse strain [10]. The TS/A cell line exhibited 
some features typical of human breast cancer, which prompted its use as a preclinical model, such as 
the low immunogenicity, the ability of local tumors to give rise to distant metastases and the 
heterogeneity, well evident both of morphology and metastatic ability. The TS/A cell line (also 
referred to as TSA or TS/A-pc, see [11,12] and below) and its clones were distributed to many 
laboratories worldwide and were employed for different applications, such as studies on malignant 
phenotype, pharmacologic therapeutic approaches, antitumor immune response and as a gene 
therapy model. 
A list of research studies exploiting the TS/A cell line or its cell variants is reported in the 
Supplementary Table S1. It includes (up to 2018) 276 research papers where TS/A was used as model 
system and 19 papers where it was a control model. Reviews reporting results obtained with TS/A 
and citations of the TS/A paper are also listed in the Supplementary Table S1. 
This review aims at profiling the main biological features of the TS/A model system resulting 
from literature research papers (Table 1). The two research areas where TS/A-based models yielded 
important results will be discussed in depth: tumor–host interactions and experimental gene 
therapy. 
Table 1. TS/A model: main features. 
Topics Cell variants Features Refs 
Cytoskeletal markers E1 CK8-positive [13] 
Cytokine production  
TS/A, clones and 
variants 
CSF [14–17] 
 TS/A TGF-β1 production (about 4 ng/mL) [18] 
Cytokine receptors TS/A IFN-γ receptor (1000/cell) [19] 
Gene alterations TS/A Karyotype [20] 
 TS/A and E1 p53 mutated (codon 270 Arg to His) [13,21] 
Gene expression TS/A TERT (11,000 RNA copies) [22] 
Hormone sensitivity TS/A and E1 Estrogen receptor positive [10,13] 
Immunity TS/A  Low immunogenicity [10,23,24] 
 
TS/A and engineered 
variants 
Tumor associated antigen gp70env [25] 
 TS/A  Suppressor activity [26,27] 
 TS/A 
Myeloid-derived suppressor cells 
(MDSC) 
[28–35] 
 TS/A NK resistance [36] 
 TS/A mD52 antigen [37]  
Membrane molecules TS/A Core 1 O-glycans [38] 
 TS/A Muc-1 [39] 
 TS/A Tag72 [39] 
Phenotype 
TS/A, clones and 
variants 
Heterogeneity (morphology, 
metastasis) 
[10,40,41] 
Stem cell markers TS/A Sca-1 (Ly6A/E) [42,43] 
Cancers 2019, 11, 1889 3 of 20 
Tyrosine Kinase 
membrane receptors 
TS/A p185erbB2 [39,44] 
Others TS/A Endoglin-negative  [45] 
 TS/A 
Fragile X mental retardation protein 
(FMRP), low expression 
[46] 
 TS/A 
High Mobility Group Box1 
(HMGB1)-positive 
[47] 
 TS/A Lats2 [48] 
 TS/A ST6Gal activity (present, low) [49] 
 TS/A TLR9-negative [50] 
3. Bioprofiling TS/A Cell Line 
The mammary tumor originating the TS/A cell line was isolated in a 20 months-old BALB/c 
female retired breeder and was described as a moderately differentiated adenocarcinoma [10]. Its first 
in vivo passage into a healthy BALB/c female was adapted to in vitro culture and named TS/A (Figure 
1). Several clones and cell variants were derived from TS/A and distributed worldwide. In particular, 
a TS/A subline was chosen by Guido Forni (University of Turin) for a large collaborative endeavor as 
the recipient cell for the systematic transduction of a large series of genes coding for immune 
modulators; such subline was referred to as TS/A-pc (from “parental cells”). TS/A and TS/A-pc share 
most features reviewed here, and some kind of drift occurred during the extensive amplification of 
TS/A-pc. Throughout this review, we will refer to the TS/A model system on the whole, and therefore 
incorrect terminology (such as TSA, TS/a, and so on) has been systematically corrected to “TS/A”. 
However, the Supplementary Table reports exactly the TS/A cell variant used in each referenced 
paper. 
 
Figure 1. Origin of the TS/A cell line and variants. For pictures see [51]. 
The tumor from which the TS/A cell line was derived likely had a long natural history in its host 
of origin. When tested in a growth-excision test, TS/A cells did not confer protection against a second 
challenge, thus showing a low immunogenicity [10], thereafter confirmed in other studies (see, for 
example, [23]). Such a low immunogenicity was the basis for a huge number of immunopotentiation 
studies, most of which exploiting gene therapy approaches (see next section). 
TS/A cells express the gp70env product of an endogenous retrovirus whose AH1 
immunodominant class I epitope could be recognized by cytotoxic T lymphocytes through 
presentation by H-2Ld [25]. Gp70env antigen is shared by other murine cell lines, such as the 
colorectal cancer cell line CT26. The down-regulation of the Ld observed in TS/A cells [52] is likely 
due to the immunoediting process leading to evasion from the host immune response. 
TS/A exerts a suppressive effect on the host immune response through several mechanisms, such 
as a selective loss of STAT5a/b expression in T and B lymphocytes [26], the production of 
Cancers 2019, 11, 1889 4 of 20 
transforming growth factor β1 (TGF-β1) [18], the induction of regulatory T cells [27], natural killer 
resistance [36] and the production of colony stimulating factors (CSFs) that deeply subvert 
hematopoiesis [14,15], giving rise to splenomegaly, leucocytosis and to tumor-infiltrating myeloid-
derived suppressor cells (MDSC) [29,33,53]. 
When injected subcutaneously into syngeneic BALB/c mice, TS/A cells gave rise to local tumors 
rapidly disseminating to the lungs. Metastases could also be obtained after injection of TS/A cells by 
the intravenous route, thus allowing a comparison between the dynamics of the early and late phases 
of the metastatic process [10,41]. Metastases to lungs and liver have also been obtained by orthotopic 
cell injection [54]. Like other mammary carcinoma cell lines, the growth of micrometastases at distant 
organs was found to involve the formation of filopodium-like protrusions mediated by FAK/ERK 
and Rif/mDia2 signaling [54]. 
Heterogeneity of TS/A cells was observed in adherent cultures, with areas of epithelial-like and 
fibroblast-like morphology (Figure 2), and in anchorage-independent cultures [10,40]. Subcloning 
from agar cultures allowed the isolation of two types of cell clones, both tumorigenic and metastatic, 
but with markedly different metastatic power [40]. Unexpectedly high-metastatic clones had a 
prevalent epithelial morphology, compared to the fibroblast-like pattern of low-metastatic clones. 
Gene expression profiling of several murine mammary cancer cell lines showed clustering of TS/A-
E1 (a high-metastatic clone) with high-claudin expressors [13]. Our data on gene expression profiling 
of TS/A clones showed that claudin-3 was the top overexpressed gene in high-metastatic clones 
(about 90-fold expression over low-metastatic clones), while low-metastatic clones overexpressed 
nme4 and necdin, two putative metastasis suppressor genes (our unpublished results). These data 
suggest that metastatic ability is not always a consequence of epithelial–mesenchymal transition but 
can also be acquired in an epithelial-like differentiation context. 
 
Figure 2. Morphology of the TS/A cell line in adherent culture (phase contrast, ×100). 
The TS/A cell line has a triploid karyotype [20] and carries a mutated p53 at codon 270 [21]. 
About a third of the cells express the cancer stem cell marker Sca-1 [43]. In our laboratory, the 
expression of Sca-1 (also known as Ly6A) was almost negative, but inducible by IFN-γ [12]. TS/A cells 
express estrogen receptor [10] and endogenous murine p185-erbB2 product [39]. Its use as a negative 
HER2/neu mammary cancer cell line in studies on HER2/neu transgenic models relies upon the 
negativity to the reagent specifically recognizing rat HER2/neu. 
4. Tumor–Host Interaction Studies 
TS/A-induced tumors have a rich and heterogeneous infiltrate comprising granulocyte and 
monocyte/macrophage subpopulations, whose relative proportions change during tumor 
progression [55], in agreement with the known plasticity of myeloid cells. Several subpopulations 
contribute to maintainance of a tumor-promoting microenvironment in TS/A, as well as in many 
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other murine and human tumors [56], with a variety of mechanisms. Alternatively-activated M2 
macrophages are strong producer of the immunosuppressive cytokine IL10 and of several 
chemokines recruiting Treg, Th2, eosinophils and basophils [56]. MDSC are heterogeneous immature 
CD11b+/Gr-1+ populations [57], with immunosuppressive function. Both M2-polarized macrophages 
and MDSC have been investigated in the TS/A model system, along with strategies to circumvent 
tumor promotion, pushing infiltrate cells towards more differentiated, activated cells. 
In the TS/A model, the induction of M2 tumor-associated macrophages was mediated by the 
expression of the CD20 homolog MS4A8A gene [58]. In TS/A tumors, M2-polarized macrophages 
were more abundant and more proangiogenic in hypoxic tumor areas [55]. The M2 immune 
suppressing phenotype was switched to an anti-tumor M1 phenotype through the in vivo adenoviral 
gene transfer of the chemokine CCL16 [59]. Alternatively-activated M2 macrophages expressed 
highly restricted, individual-specific, combinatorial T cell receptor-αβ immunoreceptors, suggestive 
of an adaptive response of macrophages to the tumor [60]. In TS/A, as well as in a variety of other 
murine and human tumors, alternatively-activated M2 tumor-associated macrophages expressed a 
multifunctional scavenger receptor named stabilin-1 involved in endocytic and phagocytic clearance 
of “unwanted-self” components, including soluble component of extracellular matrix SPARC (a 
tumor-inhibiting agent). Stabilin-1 was found to play a tumor promoting role in the TS/A model likely 
through enhanced clearance of SPARC [61]. 
A major component of TS/A infiltrate consisted of MDSC [53], which correlated with the 
production of CSFs by TS/A cells [14,29]. Immature myeloid progenitors can be released in the 
bloodstream, giving rise to peripheral leukocytosis and splenomegaly [14,15]. MDSC suppressed 
antigen-activated T lymphocytes through apoptosis induction [28,29], and suppressed NK 
cytotoxicity [62], with mechanisms involving nitric oxide [30]. Impaired anti-tumor immune response 
in aging can take advantage of an increased MDSC infiltrate [32]. MDSC expressed Fas–FasL and 
caspases, suggesting that Fas–FasL apoptosis regulated MDSC survival [33,34] and proposing new 
potential therapeutic options. MDSCs are key drivers of resistance to antiangiogenic therapy, but all-
trans retinoic acid was able to induce differentiation of MDSC into mature cells, thus increasing the 
efficacy of the antiangiogenic therapy [63]. 
In the TS/A microenvironment, other non-tumoral cell types can play a tumor-promoting role, 
such as tumor-associated fibroblasts and adipocytes. Through a tumor-stromal cell co-injection 
model, novel candidate tumor-associated genes were identified in tumor-associated fibroblasts. The 
most studied gene was tubulin tyrosine ligase: its downregulation in tumor-associated fibroblasts 
promoted TS/A tumor growth [64]. Co-culture of TS/A cells with adipocytes caused an increased 
lipid content in TS/A cells and an increased lung colonization ability [65]. The release of free fatty 
acids from lipid droplets is mediated by an adipose triglyceride lipase-dependent lipolytic pathway, 
that was proposed as a potential therapeutic target. The metabolic cross-talk between tumor cells and 
tumor-associated adipocytes could favor epithelial-mesenchymal transition and increase tumor 
invasiveness. 
TS/A cells, like other tumor cell lines, secrete membrane vesicles of endosomal origin called 
“exosomes”, with contradictory roles in tumor biology. Exosomes could have some 
immunostimulatory effect, since they carry tumor antigens which can be transferred to dendritic cells 
and cross-prime cytotoxic T lymphocytes [66]. However, exosomes mainly exerted a potent 
immunosuppressive anti-tumor immune response through suppression of NK cell function [67] and 
inhibition of differentiation of bone marrow dendritic cells [68]. Tumor-derived exosomes released 
from irradiated TS/A cells showed an altered molecular composition and were able to transfer 
dsDNA to dendritic cells and stimulate upregulation of costimulatory molecules and STING-
dependent activation of IFN-I [69]. 
5. Gene Therapy Studies 
TS/A cells were easily transduced both with naked DNA and viral systems, generating good and 
stable transgene expression of secreted factors or membrane molecules. Most gene therapy 
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approaches were performed to directly increase TS/A immunogenicity with the purpose to use 
engineered cells as anticancer vaccines (Table 2). 
Table 2. TS/A in gene therapy studies aiming to increase tumor immunogenicity. 
Immune categories Transgenes Vector/transfer methods Refs 
Chemokines h-CCL16/LEC Naked DNA + lipofection [70,71] 
  Adenoviral, in vivo [59,72] 
Cytokines m-IL2 Naked DNA + electroporation [11,23,73–77] 
 m-IL4 Retroviral [73,74,78–85] 
 m-IL5 Retroviral [86,87] 
 m-IL6 Retroviral [74,80,87] 
 m-IL7 Naked DNA + electroporation [73,74,80,81,88,89] 
 m-IL7 Adenoviral [90] 
 m-IL10 Naked DNA + electroporation [74,91]  
 m-IL12 p35 and p40 Naked DNA, in vivo [92,93] 
  Naked DNA + gene gun [94] 
  Naked DNA + lipofection [95] 
  Retroviral  [96,97] 
  Canarypox [98] 
  Naked DNA + gene gun, in vivo [24] 
 h-IL13 Naked DNA + calcium phosphate [99] 
 m-IL15 Adenoviral [100] 
 IL15 Naked DNA + lipofection [95,101] 
 Pro-IL18 and ICE Naked DNA + gene gun [94] 
 m-IL21 Naked DNA + lipofection [102] 
 m-IFNα1 Naked DNA + electroporation [80,82,103–106] 
 m-IFNα1 Naked DNA + gene gun [107] 
 m-IFNα4 Naked DNA + polymer [108] 
 m-IFNβ Naked DNA + calcium phosphate [109] 
 m-IFNγ Naked DNA + lipofection [12,74,80,99,110–113] 
 m-GMCSF Retroviral [74] 
 m-TNFα Retroviral [74,80] 
Membrane molecules B7-1/CD80 Naked DNA [114] 
  Naked DNA + electroporation [115,116] 
  Retroviral [81,89] 
 B7-2/CD86 Naked DNA + electroporation [115,116] 
 Allogeneic MHC Naked DNA + calcium phosphate [111,117] 
 CD70 (CD27L) Retroviral [118,119] 
 CD153 (CD30L) Retroviral [118] 
 CD154 (CD40L) Retroviral [118,120] 
 TRAIL/APO2L Naked DNA + lipofection [121] 
 LAG-3 and LAG5 Naked DNA + electroporation [122,123] 
 CCR7 Naked DNA + calcium phosphate [124] 
Suicide genes Cytosine deaminase Retroviral [112,125] 
  Naked DNA [126] 
  VSV (oncolytic) [127,128] 
 
HSV-Thymidine 
kinase 
Naked DNA [104] 
  Retroviral [129] 
  Naked DNA + lipofection [130] 
Others CIITA Naked DNA + lipofection [131–133] 
 GBP1 
Retroviral (conditional) + naked 
DNA 
[134] 
 m-IRF1 Adenoviral [135] 
Genes for a variety of cytokines, costimulatory molecules and major histocompatibility complex 
(MHC) antigens were inserted and stably expressed in TS/A cells. Cytokine transduction in TS/A cells 
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was often performed isolating clones with different levels of cytokine production, and this allowed 
to study the dose-related effects, such as the minimal cytokine release level required to significantly 
impact on tumor growth and immunogenicity and the potential side effects of highly-releasing cells. 
As an example, IFN-γ transduction led to isolate clones with cytokine production ranging from a few 
IU/ml up to a very high expressor clone (releasing 6000 IU/ml), likely the highest transduced 
expression ever obtained. Such a panel of IFN-γ releasing clones showed a dose-related growth 
inhibition and immunogenicity, but also showed potentially important side effects, such as increased 
lung colonizing ability and other systemic effects [12,136]. 
The wide portfolio of TS/A cells transduced with different cytokine genes allowed to understand 
the role played by each cytokine in the modulation of tumor infiltrate composition and its impact on 
tumor growth [137]. A major role for granulocytes in cytokine-induced tumor debulking was 
unexpectedly found, along with a continuous cross-talk between leukocytes and lymphocytes. The 
transduced cytokine drove the composition of the reactive cells elicited, the efficacy of the anti-tumor 
reaction and the immune memory against the non-transduced tumor. The increased memory reaction 
is the basis for the use of gene-engineered cells as anticancer vaccines. On the whole, data obtained 
with engineered TS/A vaccines (Table 2) showed that the most effective cytokines were IFN-γ and IL-12. 
TS/A transduction with GM-CSF was performed only once [74], with almost no effect on tumor 
growth or immunogenicity. On the contrary, GM-CSF engineering of another murine model (B16 
melanoma) gave good results [138] and prompted clinical studies. B16 melanoma did not produce 
spontaneously GM-CSF whereas TS/A abundantly secreted CSFs [16]. The spontaneous CSF 
production in TS/A did not hamper tumor growth but likely contributed to the tumor-promoting 
environment, showing that similar cytokines could play opposite roles in tumors of different origin. 
Transduction of genes coding for activating pro-drug enzymes (suicide genes) was performed 
with the main aim to obtain more immunogenic cancer cell vaccines. It was reported that replicating 
cells were more immunogenic than dead cells [74], so prodrug activation by suicide gene products 
could switch off partially replicating cell vaccines after the start of the immune response. However, 
prodrug-induced cancer cell death itself was found to increase the specific immune response [125]. 
Suicide genes were also included in oncolytic viruses, to enhance their safety profile [128]. 
Gene therapy approaches to obtain increased TS/A cancer cell immunogenicity gave interesting 
but, at the same time, unsatisfactory results. Most approaches actually showed increased 
immunogenicity, but when challenged in therapeutic set up, a minority of mice could be cured, and 
only when therapy started at the very early phases of metastatic growth [106,112]. Similar conclusions 
could be drawn for the variety of gene therapy trials conducted in the last three decades with the 
purpose of increasing tumor immunogenicity through cytokine or costimulatory gene transduction. 
Therefore, results obtained with TS/A as well as with other experimental gene therapy models 
predicted the low efficacy found in trials. Combined gene therapy approaches showed better 
therapeutic activity and prompted new combination immune-gene therapy approaches [99,111]. 
Gene transduction was applied to the TS/A model to study cancer biology and cancer gene 
therapy (Table 3). Transduction of the wild-type p53 gene (p53wt), aiming to restore a correct p53 
signaling, was performed in vitro and in vivo with a Canarypox vector carrying p53wt, leading to 
downstream p21 expression with a proapoptotic effect that caused tumor growth inhibition [21]. 
Tumor rejection was associated with the generation of a specific antitumor immune response in a 
sarcoma model but not in TS/A, thus confirming the low immunogenicity of the TS/A model system. 
TS/A cells were transduced with luciferase gene and green fluorescent protein (GFP) variants 
and used in studies on imaging techniques (Table 3). TS/A cells were used as recipient for genes 
coding exogenous antigens as a surrogate to study features of the corresponding immune response 
(Table 3). 
Silencing approaches were performed with retro- and lenti-viral vectors and recently with 
CRISPR-Cas9 technology. Through silencing, TGF-β1 released by TS/A cells was found to play a 
suppressive role on graft-versus-tumor reaction [18]. 
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Table 3. TS/A in transduction studies of cancer biology. 
In search of new genes potentially involved in metastasis of mammary cancer, along with data 
from human histopathological samples, some studies used TS/A cells for a mechanistic 
demonstration through silencing approaches. These studies were sometimes performed in parallel 
with another popular model of murine mammary cancer (4T1), which is more metastatic than TS/A 
cells (see Section 6). The overexpression of Fragile X mental retardation protein (FMRP) was 
concordantly related to lung metastases in both models [46]. On the contrary, some disagreement 
between TS/A and 4T1 was reported concerning the role of the small GTPase Rab27a [146]. Rab27a 
was involved in exosome secretion. Its silencing inhibited tumor growth and lung metastases in the 
4T1 model, but not in TS/A. It should be noted that the authors described TS/A as a non-metastatic 
tumor model. Since TS/A is actually able to metastasize to lungs, two explanations are possible for 
such discrepancy: a) Rab27a is not an on/off determinant of metastatic power, but rather a 
quantitative modulator; b) 4T1 is a clone while TS/A is a polyclonal and heterogeneous cell line. TS/A 
extensive subculture can have led to drift phenomena with oligoclonal dominance of less metastatic 
cells, which are well represented in the cell line of origin. 
Genetic inactivation through CRISPR/CAS9 technology of the DNA mismatched repair gene 
MutL homologue 1 (MLH1) in TS/A cells, as well as in other non-mammary murine cancer models, 
led to increased immunogenicity due to accumulation of neoantigens [147]. MLH1-inactivated cells 
acquired sensitivity to antibodies against checkpoint inhibitors, which now represent the forefront of 
cancer immunotherapy. 
Gene categories Transgenes Vector/transfer methods Refs 
Oncosuppressors m-p53wt Canarypox [21] 
 m-p53wt/mut VSV (oncolytic) [139] 
Reporter genes Luciferase Naked DNA [140,141] 
 β-galactosidase Naked DNA + polyfection [142] 
 GFP Adenoviral [143] 
 GFP Lentiviral [46] 
 EGFP Lentiviral [54] 
 EGFP Naked DNA + electroporation [50] 
 
EGFP (driven by p21 or CMV 
promoter) 
Naked DNA + electroporation [144,145] 
Silencing  antisense m-TGF-β1 Retroviral [18] 
 Rab27a Lentiviral [146] 
 Mlh1 CRISPR-Cas9 [147] 
 FoxP3 Lentiviral siRNA [44] 
 
fragile X mental retardation protein 
(FMRP) 
Lentiviral shRNA [46] 
Surrogate antigens β-galactosidase Retroviral [81,148–
150] 
 Hemagglutinin Naked DNA + lipofection [151,152] 
 
Leishmania receptor for activated C 
kinase (LACK) 
Naked DNA [153–155] 
 
Mycobacterial cell wall-associated 19-
kDa lipoprotein 
 [156] 
 Ovalbumin Naked DNA  [157,158] 
Others 
Chromogranin A (Vasostatin-1 
fragment) 
Naked DNA + electroporation [159–161] 
 
Extracellular domain of receptor 
tyrosine kinase Tie2/TEK (ex-TEK) 
Naked DNA + calcium 
phosphate precipitation 
[162] 
 Apelin Naked DNA + polyfection [163] 
 Interferon-regulatory factor-1 (IRF-1) Adenoviral [43] 
 α1,2fucosyltransferase Naked DNA + lipofection [164] 
 P27VP22 Naked DNA + polyfection [165] 
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The expression of murine ErbB2 in TS/A cells was exploited to provide experimental evidence 
of the oncosuppressor role of FoxP3 in mammary cancers, that downmodulated the expression of the 
ErbB2 oncogene [44]. TS/A cells was also used as a model to study optimization of parameters of gene 
electrotransfer [50]. 
6. Comparison with Other Mammary Cancer Models 
Modeling mammary cancer in mouse to study tumor–host interactions took advantage of 
several model systems [3,4,166]. Reordering models according to their intrinsic complexity, we can 
mention transplantable murine tumors, gene-driven mammary carcinogenic models, human cell 
lines grown in vitro or in vivo as xenografts and patient-derived xenografts and organoids. 
Concerning transplantable murine mammary cancer, the most popular cell line is 4T1, derived 
from a spontaneous mammary cancer arisen in a BALB/cfC3H female [167–169]. 4T1 share several 
features with TS/A and with human mammary cancers, such as low immunogenicity and tumor–host 
interactions. In fact, several studies were performed using in parallel 4T1 and TS/A (see for example 
Supplementary Table S1, column N), which were considered as biological replicates and generally 
gave concordant results. We can focus here on the main differences between the two models. 4T1 is 
a thioguanine-resistant clone derived from a heterogeneous mammary cancer cell line [167,168]. TS/A 
is a cell line with heterogeneity spanning from morphology to metastatic ability and to CSF 
production (and therefore tumor–host interactions), as proven by the in vitro isolation of clones with 
markedly different features [14,40]. Populations with different abilities to metastasize were also 
isolated from TS/A through in vivo selection procedures [41]. Heterogeneity is a hallmark of 
mammary cancer, which comprises morphology, differentiation and metastatic ability, but cloned 
populations at least partially lose such heterogeneity. 4T1 is a highly aggressive clone, with the ability 
to give rise to a high number of lung metastases following subcutaneous, intravenous or orthotopic 
cell injections (see for example [146]). Moreover, 4T1 can metastasize to other organs (such as liver 
and bone) [170]. TS/A is a cell line provided with metastatic ability but giving rise to moderate 
number of lung metastases following local growth, subcutaneous and intravenous injections or 
orthotopic administration [10,54]. The lower metastatic ability of the TS/A model can allow to study 
a wider range of metastasis modulators. 
In the last three decades the research on mammary tumor development and malignancy took 
advantage of transgenic models. One of the most studied models of gene-driven mammary 
carcinogenesis was that based on the rat HER2/neu oncogene under the transcriptional control of the 
Mouse Mammary Tumor Virus (MMTV) promoter [171,172]. Transgenic models recapitulated all the 
transitions from the normal mammary gland to mammary cancer, both from morphological and 
molecular points of view, and led to essential advancement in comprehension of the carcinogenic 
process and development of new therapeutic approaches. The reproducible carcinogenic process 
observed in transgenic models was exploited to study the prevention of tumor progression, including 
approaches based on immune strategies [173]. Transgene expression is somewhat artificial, 
concerning both the xenogeneic origin of the oncogene (rat HER2/neu) and the expression driven by 
a viral promoter. From an immunological point of view, the fast carcinogenesis and the altered 
immunoreactivity of mice being tolerant to transgene can be significant differences from the human 
pathogenetic development of mammary cancer. However, the main problems of transgenic models 
are time-consuming procedures and costs. Cell lines from spontaneous mammary cancer such as 
TS/A therefore are still widely employed in studies on biological features and new therapeutic 
approaches. 
Human models for mammary cancer comprise cell lines and xenografts [4,166]. Human breast 
cancer is a heterogeneous disease that, thanks to biomarkers, can be subdivided in different subtypes 
with prognostic significance [174,175] and subjected to appropriate treatments. The main advantage 
of human models is that they can reproduce the heterogeneity among tumors, giving researchers the 
possibility to choose the correct subtype depending on the aim of the research, while the main 
constraint of human cell lines and xenografts is the lack of immune tumor–host interactions. To 
identify which subtypes can be modeled by the different murine mammary cancers, a comparison 
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among gene expression profiles of a panel of murine mammary cancer cell lines including a TS/A 
variant (clone E1) and profiles of the different human subtypes was performed [13]. E1 showed a 
non-basal profile, with prevalent features of luminal A and HER2 subtypes (about 50% and 20%–30% 
probability, respectively). Therefore, a single murine model can mimic a peculiar human subtype, 
but obviously is limited to the fixed genetic setting of the cell line and does not reflect diverse 
spectrum of personalized genetic and/or epigenetic alterations of human breast cancers. 
To better depict individual mammary cancers, patient-derived xenografts (PDX) [176] and 
patient-derived organoids (PDO) were proposed [177–179]. Such approaches are more compatible 
with the need of precision oncology and without concern of species difference. PDX do not allow to 
study immune interactions (since they are grown in immunodeficient mice), and also present other 
disadvantages such as the low frequency of tumor take, with a bias toward more aggressive subtypes 
[180], the cost and the time-consuming procedure. PDO are 3D cultures obtained by dissociated 
tumor tissue which can be co-cultured with human lymphocytes, thus allowing to investigate tumor 
microenvironment, anticancer immunotherapy, and other aspects including development of novel 
therapeutics [181,182]. 
In conclusion, preclinical models of murine mammary cancer cell lines are still widely used 
thanks to their possibility to focus on tumor–host interactions comprising the role of stroma, the 
metastatic process and immune responses. The recent burst of immune-based anti-cancer therapies 
(see for example checkpoint inhibitors [133,147] and CAR-T [183]) likely will take advantage of 
murine models comprising mammary cancer cell lines. Other advantages are the low cost and time 
to obtain results. The possibility to study in parallel several cancer cell lines mimicking different 
breast cancer subtypes could remain a first-line means to study innovative molecular and therapeutic 
approaches, which will be then tested in individually precise, more complex human models. 
7. Conclusions 
The analysis of the main studies exploiting TS/A as a pre-clinical model of mammary cancer 
allows to draft a profile spanning from molecular alterations to malignant phenotype and immune 
interactions. This profile should be considered when designing experiments based on TS/A model. 
Knowledge of this profile can allow inference about the complexity of human breast cancer. 
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Authors Year Title Source title Volume Page start Page end Type of study Category Keyword 1 Keyword 2 Keyword 3 TS/A cell variant 
Other murine cell 
lines
Nanni et al. 1983
TS/A: a new metastasizing cell line from a BALB/c 
spontaneous mammary adenocarcinoma Clin Exp Metastas 1 373 380
research 
paper BIOLMET heterogeneity immunogenicity metastasis TS/A
Lollini et al. 1984
High-metastatic clones selected in vitro from a recent 
spontaneous BALB/c mammary adenocarcinoma cell line Clin Exp Metastas 2 251 259
research 
paper BIOLMET heterogeneity in vitro selection metastasis TS/A clones
Forni et al. 1985
Lymphokine-activated tumor inhibition in vivo. I. The local 
administration of interleukin 2 triggers nonreactive 
lymphocytes from tumor-bearing mice to inhibit tumor 
growth J Immunol 134 1305 1311
control 
model TUMIMM immune activation IL2 growth inhibition TS/A CE-2
Giovarelli et al. 1985
Alloantigen-activated lymphocytes from mice bearing a 
spontaneous "nonimmunogenic" adenocarcinoma inhibit 
its growth in vivo by recruiting host immunoreactivity J Immunol 135 3596 3603
research 
paper TUMIMM immune activation alloantigens growth inhibition TS/A CE-2
Lollini et al. 1985 In vivo reexpression of H-2 antigens in B16 melanoma cells Exp Clin Immunogenet 2 14 23
control 
model TUMIMM H-2 interferon in vivo growth TS/A B16 variants
Nicoletti et al. 1985
Colony-stimulating activity from the new metastatic TS/A 
cell line and its high- and low-metastatic clonal derivatives Br J Cancer 52 215 222
research 
paper BIOLMET microenvironment CSF metastasis
TS/A, TS/A 
clones
Werling et al. 1985
Adhesion and spreading characterization of a rat tumor cell 
system exhibiting different metastatic behavior Invas Metast 5 270 294
control 
model BIOLMET rat tumor cell system adhesion metastasis TS/A
Cofano et al. 1986
Binding of murine 125I-labelled natural interferon-gamma 
to murine cell receptors J Gen Virol 67 1205 1209
research 
paper BIOLMET IFNgamma growth inhibition TS/A L1210, L-929
De Giovanni et al. 1986
Dexamethasone modulation of in vitro growth pattern and 
of lung colonization ability in clones of a metastatic BALB/c 
mammary carcinoma cell line Clin Exp Metastas 4 13 23
research 
paper BIOLMET heterogeneity dexamethasone metastasis
TS/A, TS/A 
clones
Forni et al. 1986
Effect of prolonged administration of low doses of dietary 
retinoids on cell-mediated immunity and the growth of 
transplantable tumors in mice J Natl Cancer I 76 527 533
research 
paper TUMIMM immune activation retinoids growth inhibition TS/A
Nanni et al. 1986
Clones with different metastatic capacity and variant 
selection during metastasis: a problematic relationship J Natl Cancer I 76 527 533
research 
paper BIOLMET heterogeneity in vivo selection metastasis
TS/A in vivo 
selected 
variants
Nanni et al. 1986
RMZ: A new cell line from a human alveolar 
rhabdomyosarcoma. in vitro expression of embryonic 
myosin Br J Cancer 54 1009 1014 citation
Clark et al. 1987
Morphological and metastatic murine melanoma variants: 
Motility, adhesiveness, cell surface and in vivo properties Br J Cancer 56 577 584 citation
De Giovanni et al. 1987
Heterogeneity and clonal interactions in the TS/A murine 
mammary adenocarcinoma Adv Exp Med Biol 233 5 14
research 
paper BIOLMET heterogeneity clonal interactions metastasis TS/A clones
Giovarelli et al. 1987
In vitro and in vivo immunomodulatory activity of an N-9 
arginyl hypoxanthine derivative (PCF-39) Int J Immunopharmaco 9 659 667
research 
paper TUMIMM immune activation PCF39 growth inhibition TS/A
Lollini et al. 1987
Interferon-mediated modulation of metastasis and MHC 
antigens Adv Exp Med Biol 233 129 139 citation
Lollini et al. 1987
Interferon-mediated enhancement of metastasis. Are MHC 
antigens involved? Clin Exp Metastas 5 277 287 citation
Nicoletti et al. 1987
Are colony-stimulating factor-producing cells facilitated in 
the metastatic process? Anticancer Res 7 695 700
research 
paper BIOLMET heterogeneity CSF metastasis
TS/A in vivo 
selected 
variants
Fassio et al. 1988
Functional characterization of murine cell lines expressing 
high, intermediate, or negative levels of surface receptors 
for interferon- gamma J Interferon Res 8 333 341
research 
paper BIOLMET IFNgamma antiviral activity growth inhibition TS/A
EL-4, L1210, K-
BALB
Garbisa et al. 1988
Different metastatic aggressiveness by murine TS/A clones: 
ultrastructure, extracellular glycoproteins and type IV 
collagenolytic activity Invas Metast 8 177 192
research 
paper BIOLMET heterogeneity type IV collagenase metastasis TS/A clones BALB/3T3
Murphy et al. 1988
Mechanisms of organ selective tumour growth by 
bloodborne cancer cells Br J Cancer 57 19 31 citation
Lollini et al. 1989
Modulation by IFN-gamma of the metastatic ability of 
murine, human, and H-2-transfected tumor cells Tumori 75 383 388
research 
paper BIOLMET H-2 IFNgamma metastasis TS/A clones B16, B78H1
Nanni et al. 1989
Human rhabdomyosarcoma cells in nude mice as a model 
for metastasis and differentiation Invas Metast 9 231 241 citation
Nicoletti et al. 1989
In vivo and in vitro production of haemopoietic colony-
stimulating activity by murine cell lines of different origin: a 
frequent finding Eur J Cancer Clin Oncol 25 1281 1286
research 
paper BIOLMET microenvironment CSF leukocytosis TS/A-E1
B16 and 
others
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Bosco et al. 1990
Low doses of IL-4 injected perilymphatically in tumor-
bearing mice inhibit the growth of poorly and apparently 
nonimmunogenic tumors and induce a tumor-specific 
immune memory J Immunol 145 3136 343
research 
paper TUMIMM immune activation IL4 immune memory TS/A CE-2
Hock et al. 1991
Interleukin 7 induces CD4+ T cell-dependent tumor 
rejection J Exp Med 174 1291 1298
research 
paper TUMIMM/GT
engineered cancer 
cells IL7 growth inhibition TS/A J558L
Cavallo et al. 1992
Role of neutrophils and CD4+ T lymphocytes in the primary 
and memory response to nonimmunogenic murine 
mammary adenocarcinoma made immunogenic by IL-2 
gene J Immunol 149 3627 3635
research 
paper TUMIMM/GT
engineered cancer 
cells IL2 growth inhibition TS/A
Lollini et al. 1992
Ly-6A/E gene is widely expressed among transformed 
nonhematopoietic cells. Autocrine modulation by 
interferon Anticancer Res 12 2245 2252
research 
paper TUMIMM autocrine production IFNalpha/beta Ly-6A/E TS/A
B16 and 
others
Cavallo et al. 1993
Protective and curative potential of vaccination with 
interleukin-2-gene-transfected cells from a spontaneous 
mouse mammary adenocarcinoma Cancer Res 53 5067 5070
research 
paper TUMIMM/GT
engineered cancer 
vaccines IL2 growth inhibition TS/A-pc CE-2
Krüger-Krasagakes et al. 1993
Eosinophils infiltrating interleukin-5 gene-transfected 
tumors do not suppress tumor growth Eur J Immunol 23 992 995
research 
paper TUMIMM/GT
engineered cancer 
cells IL5 infiltrating leukocytes TS/A J558L
Lollini et al. 1993
Inhibition of tumor growth and enhancement of metastasis 
after transfection of the γ-interferon gene Int J Cancer 55 320 329
research 
paper TUMIMM/GT
engineered cancer 
cells IFNgamma metastasis TS/A
Modesti et al. 1993
Ultrastructural evidence of the mechanisms responsible for 
interleukin-4-activated rejection of a spontaneous murine 
adenocarcinoma Int J Cancer 53 988 993
research 
paper TUMIMM/GT
engineered cancer 
cells IL4 growth inhibition TS/A
Allione et al. 1994
Immunizing and curative potential of replicating and 
nonreplicating murine mammary adenocarcinoma cells 
engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, 
tumor necrosis factor alpha, granulocyte- macrophage 
colony-stimulating factor, and gamma-interferon gene or 
admixed with conventional adjuvants Cancer Res 54 6022 6026
research 
paper TUMIMM/GT
engineered cancer 
vaccines cytokines immune therapy TS/A-pc
Ferrantini et al. 1994
IFN-alpha 1 gene expression into a metastatic murine 
adenocarcinoma (TS/A) results in CD8+ T cell-mediated 
tumor rejection and development of antitumor immunity. 
Comparative studies with IFN-gamma-producing TS/A cells J Immunol 153 4604 4615
research 
paper TUMIMM/GT
engineered cancer 
vaccines IFNalpha immune therapy TS/A-pc
Musiani et al. 1994
Nature and potential of the reactive response to mouse 
mammary adenocarcinoma cells engineered with 
interleukin-2, interleukin-4 or interferon-gamma genes Nat Immun 13 93 101
research 
paper TUMIMM/GT
engineered cancer 
vaccines cytokines immune therapy TS/A-pc
Pericle et al. 1994
An efficient Th2-type memory follows CD8+ lymphocyte-
driven and eosinophil-mediated rejection of a spontaneous 
mouse mammary adenocarcinoma engineered to release IL-
4 J Immunol 153 5659 5673
research 
paper TUMIMM/GT
engineered cancer 
vaccines IL4 immune therapy TS/A-pc
Cavallo et al. 1995
Co-expression of B7-1 and ICAM-1 on tumors is required 
for rejection and the establishment of a memory response Eur J Immunol 25 1154 1162
research 
paper TUMIMM/GT
multi-engineered 
cancer vaccines
costimulatory 
molecules immune therapy TS/A-pc
J558L, EL-4, 
RMA, B16-F1
Cayeux et al. 1995
Tumor cells cotransfected with interleukin-7 and B7.1 
genes induce CD25 and CD28 on tumor-infiltrating T 
lymphocytes and are strong vaccines Eur J Immunol 25 2325 2331
research 
paper TUMIMM/GT
multi-engineered 
cancer vaccines IL7, B7 immune therapy TS/A J558L
Consalvo et al. 1995
5-Fluorocytosine-induced eradication of murine 
adenocarcinomas engineered to express the cytosine 
deaminase suicide gene requires host immune competence 
and leaves an efficient memory. J Immunol 154 5302 5312
research 
paper TUMIMM/GT
engineered cancer 
vaccines cytosine deaminase immune therapy TS/A-pc
Giovarelli et al. 1995
Local release of IL-10 by transfected mouse mammary 
adenocarcinoma cells does not suppress but enhances 
antitumor reaction and elicits a strong cytotoxic 
lymphocyte and antibody-dependent immune memory J Immunol 155 3112 3123
research 
paper TUMIMM/GT
engineered cancer 
vaccines IL10 immune therapy TS/A-pc
Lollini et al. 1995
Systemic effects of cytokines released by gene-transduced 
tumor cells: marked hyperplasia induced in small bowel by 
gamma-interferon transfectants through host lymphocytes Int J Cancer 61 425 430
research 
paper TUMIMM/GT
engineered cancer 
cells IFNgamma systemic effects TS/A-pc
Lollini and Nanni 1995
Minimal requirements for characterization of cytokine gene-
transduced tumor cells: a proposal J Natl Cancer I 87 1717 1718 review
Lollini et al. 1995
Transduction of genes coding for a histocompatibility 
(MHC) antigen and for its physiological inducer interferon-
gamma in the same cell: efficient MHC expression and 
inhibition of tumor and metastasis growth Hum Gene Ther 6 743 752
research 
paper TUMIMM/GT
multi-engineered 
cancer cells MHC, IFNgamma growth inhibition TS/A-pc
Cassoni et al. 1996
Oxytocin and oxytocin-analogue F314 inhibit cell 
proliferation and tumor growth of rat and mouse 
mammary carcinomas Int J Cancer 66 817 820
research 
paper PHARM oxytocin growth inhibition TS/A C26
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Lollini et al. 1996
Re:Randomized trial of adjuvant human interferon gamma 
versus observation in high-risk cutaneous melanoma: a 
Southwest Oncology Group study. J Natl Cancer I 88 926 927 review
Martin-Fontecha et al. 1996
Heterogeneous effects of B7-1 and B7-2 in the induction of 
both protective and therapeutic anti-tumor immunity 
against different mouse tumors. Eur J Immunol 26 1851 1859
research 
paper TUMIMM/GT
multi-engineered 
cancer vaccines
costimulatory 
molecules immune therapy TS/A-pc
Musiani et al. 1996
Role of Neutrophils and Lymphocytes in Inhibition of a 
Mouse Mammary Adenocarcinoma Engineered to Release 
IL-2, IL-4, IL-7, IL-10, IFN-α, IFN-γ, and TNF-α Lab Invest 74 146 157
research 
paper TUMIMM/GT
engineered cancer 
vaccines cytokines immune therapy TS/A-pc
Nanni et al. 1996
Therapy of murine mammary carcinoma metastasis with 
interferon gamma and MHC gene-transduced tumour cells Br J Cancer 74 1564 1569
research 
paper TUMIMM/GT
multi-engineered 
cancer vaccines IFNgamma, MHC metastasis TS/A-pc
Pericle et al. 1996
Direct killing of interleukin-2-transfected tumor cells by 
human neutrophils Int J Cancer 66 367 373
research 
paper TUMIMM/GT
engineered cancer 
cells IL2 immune therapy TS/A-pc
Pericle et al. 1996
CD44 Is a Cytotoxic Triggering Molecule on Human 
Polymorphonuclear Cells J Immunol 157 4657 4663
research 
paper TUMIMM CD44 hyaluronic acid cytotoxicity TS/A MC1
Vagliani et al. 1996
Interleukin 12 potentiates the curative effect of a vaccine 
based on interleukin 2-transduced tumor cells Cancer Res 56 467 470
research 
paper TUMIMM/GT
engineered cancer 
vaccines IL2 systemic rIL12 TS/A C-26, C-51
Zitvogel et al. 1996
Therapy of murine tumors with tumor peptide-pulsed 
dendritic cells: Dependence on T cells, B7 costimulation, 
and T helper cell 1-associated cytokines J Exp Med 183 87 97
research 
paper TUMIMM
peptide-pulsed 
dendritic vaccine tumor antigens growth inhibition TS/A MCA205
Zitvogel et al. 1996
Interleukin-12 and B7.1 co-stimulation cooperate in the 
induction of effective antitumor immunity and therapy of 
established tumors Eur J Immunol 26 1335 1341
research 
paper TUMIMM/GT
multi-engineered 
cancer vaccines IL12, B7 growth inhibition TS/A MCA207
Cavallo et al. 1997
Antitumor efficacy of adenocarcinoma cells engineered to 
produce interleukin 12 (IL-12) or other cytokines compared 
with exogenous IL-12 J Natl Cancer I 89 1049 1058
research 
paper TUMIMM/GT
engineered cancer 
vaccines Cytokines systemic rIL12 TS/A-pc
Cayeux et al. 1997
Influence of gene-modified (IL-7, IL-4, and B7) tumor cell 
vaccines on tumor antigen presentation J Immunol 158 2834 2841
research 
paper TUMIMM/GT
multi-engineered 
cancer vaccines B7, IL7, IL4 antigen presentation TS/A MCA205
Di Carlo et al. 1997
Interleukin 6 gene-transfected mouse mammary 
adenocarcinoma: Tumour cell growth and metastatic 
potential J Pathol 182 76 85
research 
paper BIOLMET/GT
engineered cancer 
cells IL6 metastasis TS/A-pc
Mackey et al. 1997
Protective immunity induced by tumor vaccines requires 
interaction between CD40 and its ligand, CD154 Cancer Res 57 2569 2574
research 
paper TUMIMM cancer cell vaccine
costimulatory 
molecules immune therapy TS/A
B16-F10, MCA-
105
Mayordomo et al. 1997
Bone marrow-derived dendritic cells serve as potent 
adjuvants for peptide-based antitumor vaccines Stem Cells 15 94 103 review
Musiani et al. 1997
Cytokines, tumour-cell death and immunogenicity: a 
question of choice Immunol Today 18 32 36 review
Pericle et al. 1997
Immunocompromised tumor-bearing mice show a selective 
loss of STAT5a/b expression in T and B lymphocytes J Immunol 159 2580 2585
research 
paper TUMIMM Immune suppression STAT5 tumor-bearing mice TS/A
Salazar-Onfray et al. 1997
Down-regulation of the expression and function of the 
transporter associated with antigen processing in murine 
tumor cell lines expressing IL-10 J Immunol 159 3195 3202 citation
Santodonato et al. 1997
Local and systemic antitumor response after combined 
therapy of mouse metastatic tumors with tumor cells 
expressing IFN-α and HSVtk: Perspectives for the 
generation of cancer vaccines Gene Ther 4 1246 1255
research 
paper TUMIMM/GT
multi-engineered 
cancer vaccines suicide gene growth inhibition TS/A-pc
Scarpa et al. 1997
Extracellular matrix remodelling in a murine mammary 
adenocarcinoma transfected with the interferon-alpha 1 
gene J Pathol 181 116 123
research 
paper BIOLMET/GT
engineered cancer 
cells IFNalpha microenvironment TS/A-pc MMF1
Stoppacciaro et al. 1997
Genetic modification of a carcinoma with the IL-4 gene 
increases the influx of dendritic cells relative to other 
cytokines Eur J Immunol 27 2375 2382
control 
model TUMIMM/GT
engineered cancer 
cells IL4 antitumor immunity TS/A C26
Tuting et al. 1997
Interferon-alpha gene therapy for cancer: retroviral 
transduction of fibroblasts and particle-mediated 
transfection of tumor cells are both effective strategies for 
gene delivery in murine tumor models Gene Ther 4 1053 1060
research 
paper TUMIMM/GT
engineered cancer 
cells IFNalpha growth inhibition TS/A MC38, B16
Belardelli et al. 1998
The induction of in vivo proliferation of long-lived CD44(hi) 
CD8+ T cells after the injection of tumor cells expressing 
IFN-α<inf>1</inf> into syngeneic mice Cancer Res 58 5795 5802
research 
paper TUMIMM/GT
engineered cancer 
vaccines IFNalpha immune therapy TS/A-pc C26
Chiaramonte et al. 1998
Is mts1 (S100A4) gene involved in the metastatic process 
modulated by gamma-interferon? Pathobiology 66 38 40
research 
paper BIOLMET mts1 IFNgamma metastasis TS/A B16, B78H1 
Coleman et al. 1998
Nonviral interferon α gene therapy inhibits growth of 
established tumors by eliciting a systemic immune 
response Hum Gene Ther 9 2223 2230
research 
paper TUMIMM/GT in vivo gene therapy IFNalpha immune therapy TS/A RENCA
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Couderc et al. 1998
Enhancement of antitumor immunity by expression of 
CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory 
molecules in tumor cells Cancer Gene Ther 5 163 175
research 
paper TUMIMM/GT
engineered cancer 
vaccines
costimulatory 
molecules immune therapy TS/A MCA207
Di Carlo et al. 1998
Local release of interleukin-10 by transfected mouse 
adenocarcinoma cells exhibits pro- and anti-inflammatory 
activity and results in a delayed tumor rejection Eur Cytokine Netw 9 61 68
research 
paper TUMIMM/GT
engineered cancer 
vaccines IL10 growth inhibition TS/A-pc
Di Carlo et al. 1998
Interaction between endothelial cells and the secreted 
cytokine drives the fate of an IL4- or an IL5-transduced 
tumour J Pathol 186 390 397
research 
paper TUMIMM/GT
engineered cancer 
vaccines IL4, IL5 microenvironment TS/A-pc
Favrot and Puisieux 1998
Application of gene transfer in cancer immunotherapy. 
From experimental data to clinical protocols Adv Exp Med Biol 451 539 541 review
Nanni et al. 1998
The immune response elicited by mammary 
adenocarcinoma cells transduced with interferon-gamma 
and cytosine deaminase genes cures lung metastases by 
parental cells. Hum Gene Ther 9 217 224
research 
paper TUMIMM/GT
multi-engineered 
cancer vaccines
IFNgamma, cytosine 
deaminase metastasis TS/A-pc
Petersson et al. 1998
Constitutive IL-10 production accounts for the high NK 
sensitivity, low MHC class I expression, and poor 
transporter associated with antigen processing (TAP)-1/2 
function in the prototype NK target YAC-1 J Immunol 161 2099 2105
control 
model TUMIMM/GT
engineered cancer 
cells IL10 antitumor immunity TS/A B16, RMA and others
Puisieux et al. 1998
Canarypox virus-mediated interleukin 12 gene transfer into 
murine mammary adenocarcinoma induces tumor 
suppression and long-term antitumoral immunity Hum Gene Ther 9 2481 2492
research 
paper TUMIMM/GT
engineered cancer 
vaccines IL12 canarypoxvirus vector TS/A
Qin et al. 1998
B cells inhibit induction of T cell-dependent tumor 
immunity Nat Med 4 627 630
research 
paper TUMIMM Immune suppression B cell-deficient mice antitumor immunity TS/A
Rossi et al. 1998
Inhibition of lung colonisation of a mouse mammary 
carcinoma by therapeutic vaccination with interferon-α 
gene-transduced tumor cells Clin Exp Metastas 16 123 128
research 
paper TUMIMM/GT
engineered cancer 
vaccines IFNalpha metastasis TS/A-pc
Sapino et al. 1998
Oxytocin receptor within the breast: biological function 
and distribution Anticancer Res 18 2181 2186
research 
paper PHARM oxytocin growth inhibition TS/A
Uckert et al. 1998
Double suicide gene (cytosine deaminase and herpes 
simplex virus thymidine kinase) but not single gene transfer 
allows reliable elimination of tumor cells in vivo Hum Gene Ther 9 855 865
research 
paper TUMIMM/GT
multi-engineered 
cancer vaccines suicide gene growth inhibition TS/A-pc
Zilocchi et al. 1998
Interferon gamma-independent rejection of interleukin 12-
transduced carcinoma cells requires CD4+ T cells and 
Granulocyte/Macrophage colony-stimulating factor J Exp Med 188 855 865 citation
Zitvogel et al. 1998
Eradication of established murine tumors using a novel cell-
free vaccine: dendritic cell-derived exosomes Nat Med 4 594 600
control 
model TUMIMM exosomes dendritic cells antitumor immunity TS/A P815
Bergamo et al. 1999
In vitro cell cycle arrest, in vivo action on solid 
metastasizing tumors, and host toxicity of the 
antimetastatic drug NAMI-A and cisplatin J Pharmacol Exp Ther 289 559 564
research 
paper PHARM ruthenium NAMI-A, cisplatin metastasis TS/A
Lewis lung 
carcinoma, 
MCA
Bronte et al. 1999
Unopposed production of granulocyte-macrophage colony-
stimulating factor by tumors inhibits CD8+ T cell responses 
by dysregulating antigen-presenting cell maturation J Immunol 162 5728 5737
research 
paper TUMIMM Immune suppression GM-CSF tumor-bearing mice TS/A CT26
Cavallo et al. 1999
Immune events associated with the cure of established 
tumors and spontaneous metastases by local and systemic 
interleukin 12 Cancer Res 59 414 421
research 
paper TUMIMM tumor-bearing mice rIL12 immune therapy TS/A-pc F1F
Cayeux et al. 1999 Direct and indirect T cell priming by dendritic cell vaccines Eur J Immunol 29 225 234
research 
paper TUMIMM dendritic cell vaccine betaGal immune therapy TS/A
CT26, 
MCA205, 
MCA57
Giovarelli et al. 1999
A 'stealth effect': Adenocarcinoma cells engineered to 
express TRAIL elude tumor-specific and allogeneic T cell 
reactions J Immunol 163 4886 4893
research 
paper TUMIMM/GT
engineered cancer 
vaccines TRAIL antitumor immunity TS/A-pc
Moro et al. 1999
Induction of therapeutic T-cell immunity by tumor targeting 
with soluble recombinant B7-immunoglobulin 
costimulatory molecules Cancer Res 59 2650 2656
research 
paper TUMIMM
costimulatory 
molecules recombinant B7 immune therapy TS/A RMA
Nanni et al. 1999 Cytokine gene therapy: hopes and pitfalls Ann Oncol 3 261 266 review
Oshikawa et al. 1999
Synergistic inhibition of tumor growth in a murine 
mammary adenocarcinoma model by combinational gene 
therapy using IL-12, pro-IL- 18, and IL-1beta converting 
enzyme cDNA P Natl Acad Sci U S A 96 13351 13356
research 
paper TUMIMM/GT
multi-engineered 
cancer vaccines
IL12, IL1beta converting 
enzyme, pro-IL18 combined gene therapy TS/A COS7
Pacor et al. 1999
In vitro down regulation of ICAM-1 and E-cadherin and in 
vivo reduction of lung metastases of TS/A adenocarcinoma 
by a lysozyme derivative Int J Mol Med 4 369 375
research 
paper BIOLMET lysozyme adhesion metastasis TS/A
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Pacor et al. 1999
Paracrine effects of IL-4 transfection on TS/A 
adenocarcinoma cells mediate reduced in vivo growth Pathol Oncol Res 5 110 116
research 
paper BIOLMET/GT
engineered cancer 
cells IL4 in vitro growth TS/A-pc
Prigent et al. 1999
Lymphocyte activation gene-3 induces tumor regression 
and antitumor immune responses Eur J Immunol 29 3867 3876
research 
paper TUMIMM/GT
engineered cancer 
vaccines LAG3 growth inhibition TS/A
MCA205, 
RENCA
Rozera et al. 1999
Interferon (IFN)-β gene transfer into TS/A adenocarcinoma 
cells and comparison with IFN-α. Differential effects on 
tumorigenicity and host response Am J Pathol 154 1211 1222
research 
paper TUMIMM/GT
engineered cancer 
vaccines IFNbeta growth inhibition TS/A
Sava et al. 1999
Treatment of metastases of solid mouse tumours by NAMI-
A: comparison with cisplatin, cyclophosphamide and 
dacarbazine Anticancer Res 19 969 972
research 
paper PHARM ruthenium NAMI-A metastasis TS/A
Lewis lung 
carcinoma
Schüler et al. 1999
T helper cell type 1-associated and cytotoxic T lymphocyte-
mediated tumor immunity is impaired in interleukin 4-
deficient mice J Exp Med 189 803 810
research 
paper TUMIMM immune activation IL4 immune therapy TS/A CT26
Thery et al. 1999
Molecular characterization of dendritic cell-derived 
exosomes. Selective accumulation of the heat shock 
protein hsc73. J Cell Biol 147 599 610
research 
paper TUMIMM exosomes hsc73 dendritic cells TS/A
Apolloni et al. 2000
Immortalized myeloid suppressor cells trigger apoptosis in 
antigen- activated T lymphocytes. J Immunol 165 6723 6730
research 
paper TUMIMM immune suppression MDSC apoptosis TS/A
CT26, L1210, 
C26
Bergamo et al. 2000
Effects of NAMI-A and some related ruthenium complexes 
on cell viability after short exposure of tumor cells Anti-Cancer Drugs 11 665 672
research 
paper PHARM ruthenium NAMI-A in vitro growth TS/A
Bishop et al. 2000
Antitumoral effect of a nonviral interleukin-2 gene therapy 
is enhanced by combination with 5-fluorouracil Cancer Gene Ther 7 1165 1171
control 
model TUMIMM/GT combination therapy IL2 antitumor immunity TS/A RENCA
Bronte et al. 2000
Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid 
progenitor capable of activating or suppressing CD8(+) T 
cells. Blood 96 3838 3846
research 
paper TUMIMM immune suppression MDSC CD8+ T cells TS/A CT26, MBL-2
Chen et al. 2000
Eradication of murine mammary adenocarcinoma through 
HSVtk expression directed by the glucose-starvation 
inducible grp78 promoter Breast Cancer Res Tr 59 81 90
research 
paper BIOLMET/GT
engineered cancer 
cells suicide gene immune memory TS/A
Douin-Echinard et al. 2000
The expression of CD70 and CD80 by gene-modified tumor 
cells induces an antitumor response depending on the 
MHC status Cancer Gene Ther 7 1543 1556
research 
paper TUMIMM/GT
multi-engineered 
cancer vaccines
costimulatory 
molecules immune therapy TS/A B16.F10
Giovarelli et al. 2000
Tumor rejection and immune memory elicited by locally 
released LEC chemokine are associated with an impressive 
recruitment of APCs, lymphocytes, and granulocytes. J Immunol 164 3206
research 
paper TUMIMM/GT
engineered cancer 
vaccines CCL16 immune therapy TS/A-pc F1F
Kammertoens et al. 2000
Combined chemotherapy of murine mammary tumors by 
local activation of the prodrugs ifosfamide and 5-
fluorocytosine Cancer Gene Ther 7 629 636
research 
paper BIOLMET/GT
engineered 
xenogeneic cells suicide gene growth inhibition TS/A GR
Magnarin et al. 2000
Increase of tumour infiltrating lymphocytes in mice treated 
with antimetastatic doses of NAMI-A Anticancer Res 20 2939 2944
research 
paper PHARM ruthenium NAMI-A metastasis TS/A
Lewis lung 
carcinoma
Martin-Fontecha et al. 2000
Vaccination with mouse mammary adenocarcinoma cells 
coexpressing B7-1 (CD80) and B7-2 (CD86) discloses the 
dominant effect of B7-1 in the induction of antitumor 
immunity J Immunol 164 698 704
research 
paper TUMIMM/GT
multi-engineered 
cancer vaccines
costimulatory 
molecules immune therapy TS/A
Meazza et al. 2000
Gene transfer of a secretable form of IL-15 in murine 
adenocarcinoma cells: effects on tumorigenicity, metastatic 
potential and immune response Int J Cancer 87 574 581
research 
paper TUMIMM/GT
engineered cancer 
vaccines IL15 metastasis TS/A-pc F1F
Mendiratta et al. 2000
Combination of interleukin 12 and interferon alpha gene 
therapy induces a synergistic antitumor response against 
colon and renal cell carcinoma Hum Gene Ther 11 1851 1862 citation
Pacor et al. 2000
In vitro growth of TS/A adenocarcinoma and of the gene 
transfected TS/A- IL4 line on biological substrates Anticancer Res 20 191 196
research 
paper TUMIMM/GT
engineered cancer 
cells IL4 in vitro adhesion TS/A
Provinciali et al. 2000
Efficacy of cancer gene therapy in aging adenocarcinoma 
cells engineered to release IL-2 are rejected but do not 
induce tumor specific immune memory in old mice Gene Ther 7 624 632
research 
paper TUMIMM/GT
engineered cancer 
vaccines IL2 aging TS/A-pc
Rakhmilevich et al. 2000
Interleukin-12 gene therapy of a weakly immunogenic 
mouse mammary carcinoma results in reduction of 
spontaneous lung metastases via a T-cell- independent 
mechanism Cancer Gene Ther 7 826 838
research 
paper TUMIMM/GT in vivo gene therapy IL12 metastasis TS/A 4T1
Rovero et al. 2000
DNA vaccination against rat Her-2/Neu p185 more 
effectively inhibits carcinogenesis than transplantable 
carcinomas in transgenic BALB/c mice J Immunol 165 5133 5142
control 
model TUMIMM/GT DNA vaccine HER2 antitumor immunity TS/A-pc TUBO
Willimsky and Blankenstein 2000
Interleukin-7/B7.1-encoding adenoviruses induce rejection 
of transplanted but not nontransplanted tumors Cancer Res 60 685 692
research 
paper TUMIMM/GT in vivo gene therapy IL7, B7 adenoviral vector TS/A CT26
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Zorzet et al. 2000
Lack of in vitro cytotoxicity, associated to increased 
G<inf>2</inf>-M cell fraction and inhibition of matrigel 
invasion, may predict in vivo-selective antimetastasis 
activity of ruthenium complexes J Pharmacol Exp Ther 295 927 933
research 
paper PHARM ruthenium NAMI-A in vitro invasion TS/A
Bergamo et al. 2001
Tumour cell uptake G2-M accumulation and cytotoxicity of 
NAMI-A on TS/A adenocarcinoma cells Anticancer Res 21 1893 1898
research 
paper PHARM ruthenium NAMI-A in vitro toxicity TS/A
Bussolati et al. 2001
111In-labeled 1, 4, 7, 10-tetraazacyclododecane- N, N′, N″, 
N‴-tetraacetic acid-Lys8-vasotocin: A new powerful 
radioligand for oxytocin receptor-expressing tumors Cancer Res 61 4393 4397
research 
paper IMAGING oxytocin targeted therapy TS/A
Cavallo et al. 2001
Interleukin 12-activated lymphocytes influence tumor 
genetic programs Cancer Res 61 3518 3523
research 
paper TUMIMM immune activation IL12
gene expression 
profiling TS/A TUBO
Cayeux et al. 2001
Decreased generation of anti-tumor immunity after 
intrasplenic immunization Eur J Immunol 31 1392 1399
research 
paper TUMIMM/GT
engineered cancer 
vaccines surrogate antigen
intrasplenic 
immunization TS/A MCA205
Dalziel et al. 2001
Mouse ST6Gal sialyltransferase gene expression during 
mammary gland lactation Glycobiology 11 407 412
research 
paper BIOLMET ST6Gal sialyltransferase mammary cancer
TS/A-MC (alias 
TS/A-pc)
De Giovanni et al. 2001
Therapy of lung metastases through combined vaccination 
with carcinoma cells engineered to release IL-13 and IFN-γ Gene Ther 8 1698 1704
research 
paper TUMIMM/GT
engineered cancer 
vaccines IFNgamma, IL13 metastasis TS/A-pc
Di Carlo et al. 2001
The intriguing role of polymorphonuclear neutrophils in 
antitumor reactions Blood 97 339 345 review
El mir et al. 2001
A combination of interleukin-2 and 60 nm cationic 
supramolecular biovectors for the treatment of established 
tumours by subcutaneous or intranasal administration Eur J Cancer 37 1053 1060
research 
paper TUMIMM/GT combination therapy IL2 immune therapy TS/A
Kummar et al. 2001
Modulation of graft-versus-tumor effects in a murine 
allogeneic bone marrow transplantation model by tumor-
derived transforming growth factor-betaI Biol Blood Marrow Tr 7 25 30
research 
paper TUMIMM/GT Immune suppression TGFβ1 graft-versus-tumor TS/A JC
Lambert et al. 2001
Intranodal immunization with tumor lysate-pulsed 
dendritic cells enhances protective antitumor immunity Cancer Res 61 641 646
research 
paper TUMIMM dendritic cell vaccine tumor lysate
intranodal 
immunization TS/A MCA-105
Martino et al. 2001
Effective anti-tumor immunity induced in mice by a two-
step vaccination protocol In Vivo 15 425 428
research 
paper TUMIMM/GT
engineered cancer 
vaccines mycobacterial antigen immune memory TS/A
Odin et al. 2001
Canarypox virus expressing wild type p53 for gene therapy 
in murine tumors mutated in p53 Cancer Gene Ther 8 87 98
research 
paper GT cancer gene therapy p53 canarypoxvirus vector TS/A
Pastorino et al. 2001
Generation of high-titer retroviral vector-producing 
macrophages as vehicles for in vivo gene transfer Gene Ther 8 431 441
research 
paper GT
engineered 
macrophages EGFP in vivo gene transfer TS/A
Neuro2A, CE-
2, NIH3T3
Strasly et al. 2001
IL-12 inhibition of endothelial cell functions and 
angiogenesis depends on lymphocyte-endothelial cell cross-
talk J Immunol 166 3890 3899
research 
paper TUMIMM microenvironment rIL12 angiogenesis TS/A
Wolfers et al. 2001
Tumor-derived exosomes are a source of shared tumor 
rejection antigens for CTL cross-priming Nat Med 7 297 303
research 
paper TUMIMM exosomes CTL antitumor immunity TS/A MC38
Bergamo et al. 2002
Ruthenium-based NAMI-A type complexes with in vivo 
selective metastasis reduction and in vitro invasion 
inhibition unrelated to cell cytotoxicity Int J Oncol 21 1331 1338
research 
paper PHARM ruthenium NAMI-A metastasis TS/A B16-F10, Lewis lung carcinoma
Chtarbova et al. 2002
Murine Nr4a1 and Herpud1 are up-regulated by Wnt-1, but 
the homologous human genes are independent from β-
catenin activation Biochem J 367 723 728
control 
model BIOLMET cell signaling Wnt1 tumor-bearing mice TS/A C57-MG
Colombo and Trinchieri 2002 Interleukin-12 in anti-tumor immunity and immunotherapy Cytokine Growth F R 13 155 168 review
Colombo et al. 2002
Chromogranin A expression in neoplastic cells affects 
tumor growth and morphogenesis in mouse models Cancer Res 62 941 946
research 
paper  BIOLMET/GT
engineered cancer 
cells chromogranin A growth inhibition TS/A RMA
Comes et al. 2002
IFN-γ-independent synergistic effects of IL-12 and IL-15 
induce anti-tumor immune responses in syngeneic mice Eur J Immunol 32 1914 1923
research 
paper TUMIMM/GT
multi-engineered 
cancer vaccines IL12, IL15 antitumor immunity TS/A-pc F1F
Donnini et al. 2002
Phenotype, antigen-presenting capacity, and migration of 
antigen-presenting cells in young and old age Exp Gerontol 37 1097 1112
research 
paper TUMIMM immunogenicity antigen presentation aging TS/A TUBO
Dunussi-Joannopoulos et al. 2002
Efficacious immunomodulatory activity of the chemokine 
stromal cell-derived factor 1 (SDF-1): local secretion of SDF-
1 at the tumor site serves as T-cell chemoattractant and 
mediates T-cell-dependent antitumor responses Blood 100 1551 1558
control 
model TUMIMM hSDF1 CXCR4 antitumor immunity TS/A C1498, B16F1
Fernandez et al. 2002
Genetically engineered vesicular stomatitis virus in gene 
therapy: application for treatment of malignant disease J Virol 76 895 904
research 
paper BIOLMET/GT oncolytic virotherapy IL4/TK VSV TS/A B16-F10
Grangeon et al 2002
In vivo induction of antitumor immunity and protection 
against tumor growth by injection of CD154-expressing 
tumor cells Cancer Gene Ther 9 282 288
research 
paper TUMIMM/GT
engineered cancer 
vaccines
costimulatory 
molecules antitumor immunity TS/A B16-F10
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Gri et al. 2002
Antitumor effect of interleukin (IL)-12 in the absence of 
endogenous IFN-γ: A role for intrinsic tumor 
immunogenicity and IL-15 Cancer Res 62 4390 4397
research 
paper TUMIMM/GT
engineered cancer 
vaccines IL12 growth inhibition TS/A C26
Grizzle et al. 2002
BXD recombinant inbred mice represent a novel T cell-
mediated immune response tumor model Int J Cancer 101 270 279
research 
paper TUMIMM immunogenicity BXD mice metastasis TS/A
Marionneau et al. 2002
Norwalk virus binds to histo-blood group antigens present 
on gastroduodenal epithelial cells of secretor individuals Gastroenterology 122 1967 1977
control 
model BIOLMET ABH antigens fucosyltransferase Norwalk virus TS/A
Mazzoni et al. 2002
Myeloid suppressor lines inhibit T cell responses by an NO-
dependent mechanism J Immunol 168 689 695
research 
paper TUMIMM immune suppression MDSC nitric oxide TS/A
Provinciali et al. 2002
Reactive oxygen species modulate Zn2+-induced apoptosis 
in cancer cells Free Radic Biol Med 32 431 445
research 
paper BIOLMET
reactive oxygen 
species zinc Apoptosis TS/A
Quaglino et al. 2002
Immunological prevention of spontaneous tumors: A new 
prospect? Immunol Lett 80 75 79 review
Sava et al. 2002
Influence of chemical stability on the activity of the 
antimetastasis ruthenium compound NAMI-A Eur J Cancer 38 427 435
research 
paper PHARM ruthenium NAMI-A metastasis TS/A
Vicari et al. 2002
Reversal of tumor-induced dendritic cell paralysis by CpG 
immunostimulatory oligonucleotide and anti-interleukin 10 
receptor antibody J Exp Med 196 541 549
research 
paper TUMIMM antigen presentation CpG, IL10 antitumor immunity TS/A
C26, P815, 
B16, MC38
Akbayeva et al. 2003
Synthesis, catalytic properties and biological activity of new 
water soluble ruthenium cyclopentadienyl PTA complexes 
[(C5R5)RuCl(PTA)2] (R = H, Me; PTA = 1,3,5-triaza-7-
phosphaadamantane) Chem Commun (Camb) 264 265
research 
paper PHARM ruthenium in vitro toxicity TS/A
Bergamo et al. 2003
Distinct effects of dinuclear ruthenium(III) complexes on 
cell proliferation and on cell cycle regulation in human and 
murine tumor cell lines J Pharmacol Exp Ther 305 725 732
research 
paper PHARM ruthenium in vitro toxicity TS/A B16-F10
Chini et al. 2003
Improved radiotracing of oxytocin receptor-expressing 
tumours using the new [111In]-DOTA-Lys8-deamino-
vasotocin analogue Br J Cancer 89 930 936
research 
paper IMAGING oxytocin DOTA growth inhibition TS/A
De Palma et al. 2003
Targeting exogenous genes to tumor angiogenesis by 
transplantation of genetically modified hematopoietic stem 
cells Nat Med 9 789 795
research 
paper BIOLMET/GT
engineered 
hematopoietic stem 
cells Tie2/Tek angiogenesis TS/A
LLC, B16, 
N202.1A
Douin-Echinard et al. 2003
Involvement of CD70 and CD80 intracytoplasmic domains 
in the co-stimulatory signal required to provide an 
antitumor immune response Int Immunology 15 359 372
research 
paper TUMIMM/GT
engineered cancer 
vaccines
costimulatory 
molecules antitumor immunity TS/A
Jentsch et al. 2003
Seven-fluorochrome mouse M-FISH for high-resolution 
analysis of interchromosomal rearrangements
Cytogenet Genome 
Res 103 84 88
research 
paper BIOLMET karyotype multiplex-FISH
interchromosomal 
rearrangements TS/A TUBO-AG12
Jung et al. 2003
CD3/CD28-costimulated T1 and T2 subsets: differential in 
vivo allosensitization generates distinct GVT and GVHD 
effects Blood 102 3439 3446
research 
paper TUMIMM graft-versus-tumor
costimulatory 
molecules antitumor immunity TS/A
Meazza et al. 2003
Tumor rejection by gene transfer of the MHC class II 
transactivator in murine mammary adenocarcinoma cells Eur J Immunol 33 1183 1192
research 
paper TUMIMM/GT
engineered cancer 
vaccines CIITA antitumor immunity TS/A-pc C26, F1F
Porosnicu et al. 2003
The Oncolytic Effect of Recombinant Vesicular Stomatitis 
Virus Is Enhanced
by Expression of the Fusion Cytosine Deaminase/Uracil
Phosphoribosyltransferase Suicide Gene Cancer Res 63 8366 8376
research 
paper TUMIMM/GT oncolytic virotherapy VSV growth inhibition TS/A B16F10
Provinciali et al. 2003
Low effectiveness of DNA vaccination against HER-2/neu in 
ageing Vaccine 21 843 848 citation
Roca et al. 2003
Hyperthermia inhibits angiogenesis by a plasminogen 
activator inhibitor 1-dependent mechanism Cancer Res 63 1500 1507
research 
paper BIOLMET hyperthermia PAI1 angiogenesis TS/A
Rosato et al. 2003
The cytotoxic T-lymphocyte response against a poorly 
immunogenic mammary adenocarcinoma is focused on a 
single immunodominant class I epitope derived from the 
gp70 Env product of an endogenous retrovirus Cancer Res 63 2158 2163
research 
paper TUMIMM antigen presentation gp70 antitumor immunity TS/A-pc CT26, J558
Sava et al. 2003
Dual Action of NAMI-A in inhibition of solid tumor 
metastasis: selective targeting of metastatic cells and 
binding to collagen Clin Cancer Res 9 1898 1905
research 
paper PHARM ruthenium NAMI-A metastasis TS/A
Zavaglia et al. 2003
Intercellular trafficking and enhanced in vivo antitumour 
activity of a non-virally delivered P27-VP22 fusion protein Gene Ther 100 314 325
research 
paper GT cancer gene therapy p27/HSV-VP22 non viral delivery TS/A-pc
3T3, B16 and 
others
Belicchi Ferrari et al. 2004
Synthesis, characterization and biological activity of copper 
complexes with pyridoxal thiosemicarbazone derivatives. X-
ray crystal structure of three dimeric complexes J Inorg Biochem 98 301 312
research 
paper PHARM in vitro toxicity copper complexes growth inhibition TS/A
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Cao et al. 2004
Global Gene Expression Profiling in Interleukin-12-Induced 
Activation of CD8+ Cytotoxic T Lymphocytes against Mouse 
Mammary Carcinoma Cell Mol Immunol 1 357 366
research 
paper TUMIMM immune activation IL12
gene expression 
profiling TS/A
Cappello et al. 2004
CCL16/LEC powerfully triggers effector and antigen-
presenting functions of macrophages and enhances T cell 
cytotoxicity J Leukocyte Biol 75 135 142
research 
paper TUMIMM antigen presentation CCL16 apoptosis TS/A F1F
Casarsa et al. 2004
TGFbeta1 regulation and collagen-release-independent 
connective tissue re-modelling by the ruthenium complex 
NAMI-A in solid tumours J Inorg Biochem 98 1648 1654
research 
paper PHARM ruthenium TGFbeta1 metastasis TS/A NIH3T3
Clément et al. 2004
Expression of sialyl-Tn epitopes on β1 integrin alters 
epithelial cell phenotype, proliferation and haptotaxis J Cell Sci 117 5059 5069
research 
paper BIOLMET/GT
engineered cancer 
cells sialyltransferase in vitro invasion TS/A
Cormary et al. 2004
Induction of T-cell antitumor immunity and protection 
against tumor growth by secretion of soluble human CD70 
molecules. Cancer Gene Ther 11 497 507
research 
paper TUMIMM/GT
engineered cancer 
vaccines
costimulatory 
molecules antitumor immunity TS/A
De Giovanni et al. 2004
APC10.1: An ApcMin/+ intestinal cell line with retention of 
heterozygosity Int J Cancer 109 200 206 citation
Di Carlo et al. 2004
IL-21 Induces Tumor Rejection by Specific CTL and IFN-γ-
Dependent CXC Chemokines in Syngeneic Mice J Immunol 172 1540 1547
research 
paper TUMIMM/GT
engineered cancer 
vaccines IL21 antitumor immunity TS/A-pc C26
Ferrari et al. 2004
Synthesis, characterization and biological activity of copper 
complexes with pyridoxal thiosemicarbazone derivatives. X-
ray crystal structure of three dimeric complexes J Inorg Biochem 98 301 312
research 
paper PHARM in vitro toxicity copper complexes growth inhibition TS/A
Guiducci et al. 2004
Intralesional Injection of Adenovirus Encoding CC 
Chemokine Ligand 16 Inhibits Mammary Tumor Growth 
and Prevents Metastatic-Induced Death after Surgical 
Removal of the Treated Primary Tumor J Immunol 172 4026 4036
research 
paper TUMIMM/GT in vivo gene therapy CCL16 adenoviral vector TS/A 4T1
Hahn et al. 2004
Viral vector-mediated transduction of a modified 
thrombospondin-2 cDNA inhibits tumor growth and 
angiogenesis Gene Ther 11 739 745
research 
paper BIOLMET/GT cancer gene therapy Nftsp2 angiogenesis TS/A NIH3T3
Kim et al. 2004
IRF-1 expression induces apoptosis and inhibits tumor 
growth in mouse mammary cancer cells in vitro and in vivo Oncogene 23 1125 1135
research 
paper BIOLMET/GT
engineered cancer 
cells IRF1 apoptosis TS/A C3-L5
Kurte et al. 2004
A synthetic peptide homologous to functional domain of 
human IL-10 down-regulates expression of MHC class I and 
Transporter associated with Antigen Processing 1/2 in 
human melanoma cells J Immunol 173 1731 1737 citation
Malosio et al. 2004
Dense-core granules: a specific hallmark of the 
neuronal/neurosecretory cell phenotype J Cell Sci 117 743 749
control 
model BIOLMET
engineered cancer 
cells chromogranin A
neurosecretory 
phenotype TS/A PC12
Margiotta et al. 2004
Antiviral properties and cytotoxic activity of platinum(II) 
complexes with 1,10-phenanthrolines and acyclovir or 
penciclovir J Inorg Biochem 98 1385 1390
research 
paper PHARM platinum complexes Me2phen cytotoxicity TS/A
Melani et al. 2004
Angiopoietin decoy secreted at tumor site impairs tumor 
growth and metastases by inducing local inflammation and 
altering neoangiogenesis
Cancer Immunol 
Immunother 53 600 608
research 
paper TUMIMM/GT cancer gene therapy angiopoietin decoy metastasis TS/A C26
Mitsuhashi et al. 2004
Regulation of interleukin-12 gene expression and its anti-
tumor activities by prostaglandin E2 derived from 
mammary carcinomas J Leukocyte Biol 76 322 332
research 
paper TUMIMM immune activation PGE2 systemic rIL12 TS/A 4T1
Morini et al. 2004
Prevention of angiogenesis by naked DNA IL-12 gene 
transfer: angioprevention by immunogene therapy Gene Ther 11 284 291
research 
paper TUMIMM/GT in vivo gene therapy IL12 angiogenesis TS/A
Reome et al. 2004
Type 1 and type 2 tumor infiltrating effector cell 
subpopulations in progressive breast cancer Clin Immunol 111 69 81
research 
paper TUMIMM TIL NKT antitumor immunity TS/A
Sacchi et al. 2004
Crucial role for interferon γ in the synergism between 
tumor vasculature-targeted tumor necrosis factor α (NGR-
TNF) and doxorubicin Cancer Res 64 7150 7155
research 
paper BIOLMET/GT
tumor vascular 
targeting IFNgamma doxorubicin TS/A B16
Sakai et al. 2004
Vaccination by genetically modified dendritic cells 
expressing a truncated neu oncogene prevents 
development of breast cancer in transgenic mice Cancer Res 64 8022 8028
control 
model TUMIMM/GT HER2+ breast cancer adenoviral vaccine antitumor immunity TS/A
TUBO, 
N202.1A 
Serafini et al. 2004
Derangement of immune responses by myeloid suppressor 
cells
Cancer Immunol 
Immunother 53 64 72 review
Turel et al. 2004
Solution, solid state and biological characterization of 
ruthenium(III)-DMSO complexes with purine base 
derivatives J Inorg Biochem 98 393 401
research 
paper PHARM ruthenium adhesion in vitro growth TS/A
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Velders et al. 2004
Synthesis and Chemical-Pharmacological Characterization 
of the
Antimetastatic NAMI-A-Type Ru(III) Complexes 
(Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-
RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-
S)(dmtp)] (dmtp ) 5,7 
Dimethyl[1,2,4]triazolo[1,5a]pyrimidine) J Med Chem 47 1110 1121
research 
paper PHARM ruthenium NAMI-A metastasis TS/A B16-F10
Weber et al. 2004
IL-12 cDNA direct injection: antimetastatic effect from a 
single injection in a murine hepatic metastases model J Surg Res 122 210 217
research 
paper TUMIMM/GT in vivo gene therapy IL12 metastasis TS/A
Benigni et al. 2005
Phenotype and homing of CD4 tumor-specific T cells is 
modulated by tumor bulk J Immunol 175 739 748
research 
paper TUMIMM/GT
engineered cancer 
cells CD4 homing antitumor immunity TS/A
Casares et al. 2005
Caspase-dependent immunogenicity of doxorubicin-
induced tumor cell death J Exp Med 202 1691 1701
control 
model TUMIMM immune activation doxorubicin caspase TS/A CT26,B16F10
Di Carlo et al. 2005
Immunological mechanisms elicited at the tumour site by 
lymphocyte activation gene-3 (LAG-3) versus IL-12: Sharing 
a common Th1 anti-tumour immune pathway J Pathol 205 82 91
research 
paper TUMIMM/GT
engineered cancer 
cells LAG3 antitumor immunity TS/A
Foley et al. 2005
Ex vivo rapamycin generates donor Th2 cells that potently 
inhibit graft-versus-host disease and graft-versus-tumor 
effects via an IL-4-dependent mechanism. J Immunol 175 5732 5743
research 
paper TUMIMM graft-versus-tumor rapamycin growth inhibition TS/A
Garanger et al. 2005
New multifunctional molecular conjugate vector for 
targeting, imaging, and therapy of tumors Mol Ther 12 1168 1175
research 
paper GT in vivo gene therapy alphaVbeta3 RAFT vector TS/A-pc
Guiducci et al. 2005
Redirecting in vivo elicited tumor infiltrating macrophages 
and dendritic cells towards tumor rejection Cancer Res 65 3437 3446
research 
paper TUMIMM/GT TAM CCL16 adenoviral vector TS/A MCA38, 4T1
Hsu et al. 2005 Genetic regulation of thymic involution Mech Ageing Dev 126 87 97 review
Park et al. 2005
Early role of CD4+Th1 cells and antibodies in HER-2 
adenovirus vaccine protection against autochthonous 
mammary carcinomas J Immunol 174 4228 4236
control 
model TUMIMM/GT HER2+ breast cancer in vivo gene therapy adenoviral vaccine TS/A
TUBO, 
N202.1A, 
N202.1E
Preiss et al. 2005
Tumor-induced antibodies resemble the response to tissue 
damage Int J Cancer 115 456 462
research 
paper TUMIMM
tumor-induced 
antibodies tissue damage growth inhibition TS/A
Scolaro et al. 2005
In vitro and in vivo evaluation of ruthenium(II)-arene PTA 
complexes J Med Chem 48 4161 4171
research 
paper PHARM ruthenium RAPTA-C metastasis TS/A
Agu et al. 2006
The cytotoxic activity of the bacteriophage λ-holin protein 
reduces tumour growth rates in mammary cancer cell 
xenograft models J Gene Med 8 229 241
research 
paper GT cancer gene therapy l holin growth inhibition TS/A
Come et al. 2006
CD25+regulatory T cell depletion augments 
immunotherapy of micrometastases by an IL-21-secreting 
cellular vaccine J Immunol 176 1750 1758
research 
paper TUMIMM/GT
engineered cancer 
vaccines IL21 Treg TS/A F1F
Dobrzanski et al. 2006
CD8-mediated type 1 antitumor responses selectively 
modulate endogenous differentiated and nondifferentiated 
T cell localization, activation, and function in progressive 
breast cancer J Immunol 177 8191 8201
research 
paper TUMIMM/GT antigen presentation surrogate antigen antitumor immunity TS/A
Grimaldi et al. 2006
Anandamide inhibits adhesion and migration of breast 
cancer cells Exp Cell Res 312 363 373
research 
paper PHARM anandamide CB1 receptor in vitro adhesion TS/A-E1
Liu et al. 2006
Murine mammary carcinoma exosomes promote tumor 
growth by suppression of NK cell function J Immunol 176 1375 1385
research 
paper TUMIMM exosomes NK antitumor immunity TS/A 4T1
Mortara et al. 2006
CIITA-induced MHC class II expression in mammary 
adenocarcinoma leads to a Th1 polarization of the tumor 
microenvironment, tumor rejection, and specific antitumor 
memory Clin Cancer Res 12 3435 3443
research 
paper TUMIMM/GT
engineered cancer 
vaccines CIITA immune memory TS/A C26, F1F
Richards et al. 2006
Tumor growth impedes natural-killer-cell maturation in the 
bone marrow Blood 108 246 252
research 
paper TUMIMM immune suppression NK antitumor immunity TS/A
4T1, EL-4, 
RMA-s, MC38, 
B16-F1
Schirmbeck et al. 2006
Priming protective CD8 T cell immunity by DNA vaccines 
encoding chimeric, stress protein-capturing tumor-
associated antigen J Immunol 177 1534 1542
research 
paper TUMIMM/GT DNA vaccine gp70 cancer prevention TS/A
CT26, P815, 
RBL5/EL4, 
mKSA
Scolaro et al. 2006
Influence of hydrogen-bonding substituents on the 
cytotoxicity of RAPTA compounds Organometallics 25 756 765
research 
paper PHARM ruthenium RAPTA-C drug uptake TS/A
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Serafini et al. 2006
Phosphodiesterase-5 inhibition augments endogenous 
antitumor immunity by reducing myeloid-derived 
suppressor cell function J Exp Med 203 2691 2702
research 
paper TUMIMM immune suppression MDSC antitumor immunity TS/A
CT26, 
MCA203, B16-
GM, 4T1-HA
Valzasina et al. 2006
Tumor-induced expansion of regulatory T cells by 
conversion of CD4+CD25- lymphocytes is thymus and 
proliferation independent Cancer Res 66 4488 4495
research 
paper TUMIMM immune escape Treg antitumor immunity TS/A CT26, 4T1
Vock et al. 2006
Synthesis, characterization, and in vitro evaluation of novel 
ruthenium(II) η6-arene imidazole complexes J Med Chem 49 5552 5561
research 
paper PHARM ruthenium cytotoxicity TS/A
Yurkovetsky et al. 2006
Comparative analysis of antitumor activity of CD40L, 
RANKL, and 4-1BBL in vivo following intratumoral 
administration of viral vectors or transduced dendritic cells J Gene Med 8 129 137
research 
paper TUMIMM/GT in vivo gene therapy cancer vaccines growth inhibition TS/A MC38
Braschoss et al. 2007
New anti-CD30 human pancreatic ribonuclease-based 
immunotoxin reveals strong and specific cytotoxicity in vivo Leukemia Lymphoma 48 1179 1186
research 
paper TUMIMM immunotoxin antitumor immunity TS/A
Croci et al. 2007
Expression of a functional CCR7 chemokine receptor 
inhibits the post-intravasation steps of metastasis in 
malignant murine mammary cancer cells Oncol Rep 18 451 456
research 
paper TUMIMM/GT
engineered cancer 
vaccines CCR7 metastasis TS/A N202.1A
Faneca et al. 2007
Evaluation of the antitumoral effect mediated by IL-12 and 
HSV-tk genes when delivered by a novel lipid-based system
Biochim Biophys Acta - 
Biomembranes 1768 1093 1102
research 
paper GT in vivo gene therapy lipid-based system growth inhibition TS/A
Fuchs et al. 2007
A cleavable molecular adapter reduces side effects and 
concomitantly enhances efficacy in tumor treatment by 
targeted toxins in mice J Control Release 117 342 350
research 
paper PHARM targeting saporin growth inhibition TS/A
Grizzle et al. 2007
Age-related increase of tumor susceptibility is associated 
with myeloid-derived suppressor cell mediated suppression 
of T cell cytotoxicity in recombinant inbred BXD12 mice Mech Ageing Dev 128 672 680
research 
paper TUMIMM immune suppression MDSC aging TS/A
Josserand et al. 2007
Non-invasive in vivo optical imaging of the lacZ and luc 
gene expression in mice Gene Ther 14 1587 1593
research 
paper IMAGING
engineered cancer 
cells luciferase, betaGal in vivo imaging TS/A-pc
Li et al. 2007
Cross-talk between T cells and innate immune cells is 
crucial for IFN-γ-dependent tumor rejection J Immunol 179 1568 1576
research 
paper TUMIMM immune activation IFNgamma antitumor immunity TS/A
MCA205, 
J558L
Liu et al. 2007
Expansion of spleen myeloid suppressor cells represses NK 
cell cytotoxicity in tumor-bearing host Blood 109 4336 4342
research 
paper TUMIMM immune suppression MDSC antitumor immunity TS/A YAC-1
Mortara et al. 2007
Experimental therapeutic approaches to adenocarcinoma: 
the potential of tumor cells engineered to express MHC 
class II molecules combined with naked DNA interleukin-12 
gene transfer Surg  Oncol
16, 
suppl 1 S33 S36 review
Obeid et al. 2007 Ecto-calreticulin in immunogenic chemotherapy Immunol Rev 220 22 34 review
Sancey et al. 2007
In vivo imaging of tumour angiogenesis in mice with the 
alpha(v)beta (3) integrin-targeted tracer 99mTc-RAFT-RGD. Eur J Nucl Med Mol I 34 2037 2047
research 
paper IMAGING in vivo imaging alphaVbeta3 angiogenesis TS/A-pc B16F0
Scolaro et al. 2007
Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) 
drugs to modify uptake, biomolecular interactions and 
efficacy Dalton Transactions 5065 5072
research 
paper PHARM ruthenium hydrophobicity cytotoxicity TS/A
Sorli et al. 2007 Apelin is a potent activator of tumour neoangiogenesis Oncogene 26 7692 7699
research 
paper BIOLMET/GT
engineered cancer 
cells apelin angiogenesis TS/A
Steel et al. 2007
Immunocompetent syngeneic cotton rat tumor models for 
the assessment of replication-competent oncolytic 
adenovirus Virology 369 131 142
research 
paper BIOLMET oncolytic virotherapy adenovirus growth inhibition TS/A 15-12RM
Yamano et al. 2007
Immunity against breast cancer by TERT DNA vaccine 
primed with chemokine CCL21 Cancer Gene Ther 14 451 459
research 
paper TUMIMM/GT DNA vaccine TERT antitumor immunity TS/A B16, 4T1
Yu et al. 2007
Tumor exosomes inhibit differentiation of bone marrow 
dendritic cells J Immunol 178 6867 6875
research 
paper TUMIMM exosomes dendritic cells antitumor immunity TS/A B16
Zhang et al. 2007
Curcumin reverses breast tumor exosomes mediated 
immune suppression of NK cell tumor cytotoxicity Biochim Biophys Acta 1773 1116 1123
research 
paper TUMIMM exosomes NK antitumor immunity TS/A 4T1
Zimmermann et al. 2007
Tumors hamper the immunogenic competence of CD4+T 
cell-directed dendritic cell vaccination J Immunol 179 2899 2909
research 
paper TUMIMM dendritic cell vaccine CD4+ antitumor immunity TS/A
Zuo et al. 2007
FOXP3 is an X-linked breast cancer suppressor gene and an 
important repressor of the HER-2/ErbB2 oncogene Cell 129 1275 1286
research 
paper BIOLMET/GT
engineered cancer 
cells HER2, FOXP3 growth inhibition TS/A 4T1
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Dobrzanski et al. 2008
Ag-specific type 1 CD8 effector cells enhance methotrexate-
mediated antitumor responses by modulating 
differentiated T cell localization, activation and chemokine 
production in established breast cancer Clin Immunol 37 315 338
research 
paper TUMIMM antigen presentation methotrexate antitumor immunity TS/A
Komita et al. 2008
CD8+ T-cell responses against hemoglobin-beta prevent 
solid tumor growth Cancer Res 68 8076 8084
research 
paper TUMIMM/GT
engineered dendritic 
cell vaccine hemoglobin-beta growth inhibition TS/A
CMS4,  
MethA, CT26
Piconese et al. 2008
OX40 triggering blocks suppression by regulatory T cells 
and facilitates tumor rejection J Exp Med 205 825 839
research 
paper TUMIMM Treg OX40 growth inhibition TS/A
CT26, N2C, 
MCA203
Bachran et al. 2009
Inhibition of tumor growth by targeted toxins in mice is 
dramatically improved by saponinum album in a synergistic 
way J Immunother 32 713 725
research 
paper PHARM targeting saporin growth inhibition TS/A
Bierer, B.E. 2009 Animal models for tumor immunology Curr Prot Immunol 85 20.0.1 20.0.9 review
Cai et al. 2009
Optimized systemic dosing with CpG DNA enhances 
dendritic cell-mediated rejection of a poorly immunogenic 
mammary tumor in BALB/c mice Clin Transl Sci 2 62 66
research 
paper TUMIMM dendritic cell vaccine CpG growth inhibition TS/A
Dewan et al. 2009
Fractionated but not single-dose radiotherapy induces an 
immune-mediated abscopal effect when combined with 
anti-CTLA-4 antibody Clin Cancer Res 15 5379 5388
research 
paper PHARM radiotherapy abscopal effect growth inhibition TS/A MCA38
Ghiringhelli et al. 2009
Activation of the NLRP3 inflammasome in dendritic cells 
induces IL-1beta-dependent adaptive immunity against 
tumors Nat Med 15 1170 1178
research 
paper TUMIMM immune activation inflammasome antitumor immunity TS/A
EG7, EL4, 
MCA2, CT26, 
B16F10
Hirsch et al. 2009
Anti-CD30 human IL-2 fusion proteins display strong and 
specific cytotoxicity In Vivo Curr Drug Targets 10 110 117
research 
paper TUMIMM/GT fusion protein CD30 antitumor immunity TS/A J558L
Lu et al. 2009
Responsiveness of stromal fibroblasts to IFN-γ blocks 
tumor growth via angiostasis J Immunol 183 6413 6421
control 
model TUMIMM TAF IFNalpha angiogenesis TS/A
FH32, 
MCA205, 
J558L
Mirshahidi et al. 2009
Overlapping synthetic peptides encoding TPD52 as breast 
cancer vaccine in mice: prolonged survival Vaccine 27 1825 1833
research 
paper TUMIMM
peptide-based 
vaccines tumor protein D52 antitumor immunity TS/A P815
Mortara et al. 2009
Irradiated CIITA-positive mammary adenocarcinoma cells 
act as a potent anti-tumor-preventive vaccine by inducing 
tumor-specific CD4+T cell priming and CD8+T cell effector 
functions Int Immunology 21 655 665
research 
paper TUMIMM/GT
engineered cancer 
vaccines CIITA antitumor immunity TS/A C26, F1F
Sancey et al. 2009
Drug development in oncology assisted by noninvasive 
optical imaging Int J Pharm 379 309 316
research 
paper PHARM imaging lipid-based system apoptosis TS/A-pc
Texier et al. 2009
Cyanine-loaded lipid nanoparticles for improved in vivo 
fluorescence imaging J Biomed Opt 14 54005-1 54005-11
research 
paper IMAGING targeting lipid-based system cyanine dyes TS/A-pc
Accolla et al. 2010 New strategies of mammary cancer vaccination Breast J 16 S42 S44 review
Frangione et al. 2010
CIITA-driven MHC-II positive tumor cells: preventive 
vaccines and superior generators of antitumor CD4+ T 
lymphocytes for immunotherapy Int J Cancer 127 1614 1624
research 
paper TUMIMM/GT
engineered cancer 
vaccines CIITA antitumor immunity TS/A
C51, RENCA, 
WEHI-164
Goutayer et al. 2010
Tumor targeting of functionalized lipid nanoparticles: 
assessment by in vivo fluorescence imaging Eur J Pharm Biopharm 75 137 147
research 
paper PHARM targeting lipid-based system imaging TS/A-pc
Huang et al. 2010
Deoxyelephantopin, a novel multifunctional agent, 
suppresses mammary tumour growth and lung metastasis 
and doubles survival time in mice Br J Pharmacol 159 856 871
research 
paper PHARM chemoprevention deoxyelephantopin metastasis TS/A
Kim et al. 2010
Ras activation contributes to the maintenance and 
expansion of Sca-1poscells in a mouse model of breast 
cancer Cancer Lett 287 172 181
research 
paper BIOLMET cancer stem cells Ras Sca1 TS/A
4T1, EMT6 
and CT26
Lee et al. 2010
Differential proteomic profiling identifies novel molecular 
targets of paclitaxel and phytoagent deoxyelephantopin 
against mammary adenocarcinoma cells J Proteome Res 9 237 253
research 
paper PHARM drug activity
paclitaxel, 
deoxyelephantopin proteomic profiling TS/A
Lipnik et al. 2010
Interferon γ-Induced human guanylate binding protein 1 
inhibits mammary tumor growth in mice Mol Med 16 177 187
research 
paper TUMIMM/GT
engineered cancer 
cells hGBP1 angiogenesis TS/A
Liu et al. 2010
Contribution of MyD88 to the Tumor Exosome-Mediated 
Induction of Myeloid Derived Suppressor Cells Blood 176 2490 2499 citation
Movahedi et al. 2010
Different Tumor Microenvironments Contain Functionally 
Distinct Subsets of Macrophages Derived from 
Ly6C(high)Monocytes Cancer Res 70 5728 5739
research 
paper TUMIMM immune suppression MDSC microenvironment TS/A 4T1, 3LL-R
Schiering et al. 2010
Antigen-experienced CD4+ T cells limit naïve T-cell priming 
in response to therapeutic vaccination in vivo Cancer Res 70 6161 6170
research 
paper TUMIMM cancer cell vaccine surrogate antigen antitumor immunity TS/A
2A B C D E F G H I J K L M N
Authors Year Title Source title Volume Page start Page end Type of study Category Keyword 1 Keyword 2 Keyword 3 TS/A cell variant 
Other murine cell 
lines
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
Cottone et al. 2011
Evaluation of the role of tumor-associated macrophages in 
an experimental model of peritoneal carcinomatosis using 
18F-FDG PET J Nucl Med 52 1770 1777
research 
paper IMAGING PET TAM
peritoneal 
carcinomatosis TS/A
Daftarian et al. 2011
Peptide-conjugated PAMAM dendrimer as a universal DNA 
vaccine platform to target antigen-presenting cells Cancer Res 71 7452 7462
research 
paper TUMIMM/GT
DNA-peptide-
dendrimer vaccines gp70 antitumor immunity TS/A
B16-F10, MBL-
2, CT26
Heiber and Barber 2011
Vesicular stomatitis virus expressing tumor suppressor p53 
is a highly attenuated, potent oncolytic agent J Virol 85 10440 10450
research 
paper BIOLMET/GT oncolytic virotherapy p53 VSV TS/A
mouse 
embryonic 
fibroblasts
Iezzi et al. 2011
HCG hastens both the development of mammary 
carcinoma and the metastatization of HCG/LH and ERBB-2 
receptor-positive cells in mice Int J Immunopath Ph 24 621 630
control 
model BIOLMET HER2+ breast cancer hCG metastasis TS/A TUBO 
Kamensek et al. 2011
Irradiation, cisplatin, and 5-azacytidine upregulate 
cytomegalovirus promoter in tumors and muscles: 
Implementation of non-invasive fluorescence imaging Mol Imaging Biol 13 43 52
research 
paper GT cancer gene therapy GFP CMV promoter TS/A LPB
Leveille et al. 2011
Vesicular stomatitis virus oncolytic treatment interferes 
with tumor-associated dendritic cell functions and 
abrogates tumor antigen presentation Cancer Gene Ther 85 12160 12169
research 
paper TUMIMM/GT oncolytic virotherapy antigen presentation VSV TS/A PC3, B16-F10
Li et al. 2011
Identification of a tumor suppressor relay between the 
FOXP3 and the Hippo pathways in breast and prostate 
cancers Cancer Res 71 2162 2171
research 
paper BIOLMET/GT tumor suppressor FOXP3 growth inhibition TS/A
Schmieder et al. 2011
Synergistic activation by p38MAPK and glucocorticoid 
signaling mediates induction of M2-like tumor-associated 
macrophages expressing the novel CD20 homolog MS4A8A. Int J Cancer 129 122 132
research 
paper BIOLMET TAM CD20
Gene expression 
profiling TS/A B16F1
Sinha et al. 2011
Myeloid-derived suppressor cells express the death 
receptor Fas and apoptose in response to T cell-expressed 
FasL Blood 117 5381 5390
research 
paper BIOLMET immune suppression MDSC apoptosis TS/A 4T1, AT3
Veschini 2011
The vasostatin-1 fragment of chromogranin A preserves a 
quiescent phenotype in hypoxia-driven endothelial cells 
and regulates tumor neovascularization. FASEB J 25 3906 3914
research 
paper BIOLMET/GT
engineered cancer 
cells vasostatin1 angiogenesis TS/A
Bobrie et al. 2012
Rab27a supports exosome-dependent and -independent 
mechanisms that modify the tumor microenvironment and 
can promote tumor progression Cancer Res 72 4920 4930
research 
paper BIOLMET exosomes microenvironment tumor progression TS/A 4T1
Coral et al. 2012
Epigenetic remodelling of gene expression profiles of 
neoplastic and normal tissues: Immunotherapeutic 
implications Br J Cancer 107 1116 1124
research 
paper TUMIMM epigenetic modulation
gene expression 
profiling antitumor immunity TS/A
Dewan et al. 2012
Synergy of topical toll-like receptor 7 agonist with radiation 
and low-dose cyclophosphamide in a mouse model of 
cutaneous breast cancer. Clin Cancer Res 18 6668 6678
research 
paper BIOLMET combination therapy TLR7 metastasis TS/A
Lee and Shyur 2012
Deoxyelephantopin impedes mammary adenocarcinoma 
cell motility by inhibiting calpain-mediated adhesion 
dynamics and inducing reactive oxygen species and 
aggresome formation. Free Radic Biol Med 52 1423 1436
research 
paper PHARM calpain deoxyelephantopin motility TS/A
Morandi et al. 2012
Dendritic cell editing by activated natural killer cells results 
in a more protective cancer-specific immune response PLoS ONE 7 e39170
research 
paper TUMIMM immune activation dendritic cells antitumor immunity TS/A YAC-1
Ostrand-Rosenberg et al. 2012
Regulating the suppressors: apoptosis and inflammation 
govern the survival of tumor-induced myeloid-derived 
suppressor cells (MDSC)
Cancer Immunol 
Immunother 61 1319 1325
research 
paper TUMIMM immune suppression MDSC proteomic profiling TS/A 4T1, AT3
Sedlar et al. 2012
Potentiation of electrochemotherapy by intramuscular IL-
12 gene electrotransfer in murine sarcoma and carcinoma 
with different immunogenicity Radiol Oncol 46 302 311
research 
paper GT electrochemotherapy IL12 growth inhibition TS/A SA-1
Shibue et al. 2012
The outgrowth of micrometastases is enabled by the 
formation of filopodium-like protrusions Cancer Discov 2 706 721
research 
paper BIOLMET motility
filopodium-like 
protrusions metastasis TS/A D2
Sinha et al. 2012
Tumor-induced myeloid-derived suppressor cell function is 
independent of IFN-γ and IL-4Rα Eur J Immunol 42 2052 2059
research 
paper TUMIMM immune suppression MDSC antitumor immunity TS/A
CT26, 4T1, 
B16, MC38, 
3LL
Arigoni et al. 2013
MiR-135b coordinates progression of ErbB2-driven 
mammary carcinomas through suppression of MID1 and 
MTCH2 Am J Pathol 182 2058 2070
control 
model BIOLMET HER2+ breast cancer miR-135b tumor progression TS/A 4T1, TUBO
Ben Yebdri et al. 2013
Triptolide-mediated inhibition of interferon signaling 
enhances vesicular stomatitis virus-based oncolysis. Mol Ther 21 2043 2053
research 
paper BIOLMET oncolytic virotherapy triptolide VSV TS/A PC3
Bonnet et al. 2013
Systemic delivery of sticky siRNAs targeting the cell cycle for 
lung tumor metastasis inhibition J Control Release
research 
paper GT non viral carrier siRNA metastasis TS/A 
De Medina et al. 2013
Dendrogenin A arises from cholesterol and histamine 
metabolism and shows cell differentiation and anti-tumour 
properties Nat Commun 4 1840
research 
paper PHARM differentiation therapy dendrogenin A growth inhibition TS/A B16F10
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Dolinsek et al. 2013
Multiple Delivery of siRNA against Endoglin into Murine 
Mammary Adenocarcinoma Prevents Angiogenesis and 
Delays Tumor Growth PLoS ONE 8 e58723
research 
paper GT gene silencing endoglin angiogenesis TS/A 2H11
Hirsjarvi et al. 2013
Influence of size, surface coating and fine chemical 
composition on the
in vitro reactivity and in vivo biodistribution of lipid 
nanocapsules
versus lipid nanoemulsions in cancer models
Nanomed-
Nanotechnol 9 375 387
research 
paper IMAGING targeting lipid-based system biodistribution TS/A-pc
Kamensek et al. 2013
Evaluation of p21 promoter for interleukin 12 radiation 
induced transcriptional targeting in a mouse tumor model Mol Cancer 12 136
research 
paper GT
radiation-induced 
transcriptional 
targeting p21 promoter growth inhibition TS/A
Kéramidas et al. 2013
The dual effect of mscs on tumour growth and tumour 
angiogenesis Stem Cell Res Ther 4 41
research 
paper BIOLMET hMSCs imaging angiogenesis TS/A
Lollini et al. 2013 Preclinical vaccines against mammary carcinoma Expert Rev Vaccines 12 1449 1463 review
Lucá et al. 2013
The Fragile X Protein binds mRNAs involved in cancer 
progression and modulates metastasis formation EMBO Mol Med 5 1523 1536
research 
paper BIOLMET/GT
engineered cancer 
cells FMRP Metastasis TS/A 4T1
Gravier et al. 2014
FRET Imaging Approaches for in Vitro and in Vivo 
Characterization of
Synthetic Lipid Nanoparticles Mol Pharmaceut 11 3133 3144
research 
paper IMAGING targeting lipid-based system FRET TS/A-pc
Longo et al. 2014
A general MRI-CEST ratiometric approach for pH imaging: 
Demonstration of in vivo pH mapping with iobitridol J Am Chem Soc 136 14333 14336
research 
paper IMAGING magnetic resonance Iobitridol pH TS/A
Morris et al. 2014
Vaccination with tumor cells expressing IL-15 and IL-
15Ralpha inhibits murine breast and prostate cancer Gene Ther 21 393 401
research 
paper TUMIMM/GT
engineered cancer 
vaccines IL15 antitumor immunity TS/A
TUBO, TRAMP-
C2
Bozon-Petitprin et al. 2015
Targeted radionuclide therapy with RAFT-RGD 
radiolabelled with (90)Y or (177)Lu in a mouse model of 
alphavbeta3-expressing tumours Eur J Nucl Med Mol I 42 252 263
research 
paper PHARM radiotherapy alphaVbeta3 growth inhibition TS/A-pc
Covre et al. 2015
Antitumor activity of epigenetic immunomodulation 
combined with CTLA-4 blockade in syngeneic mouse 
models OncoImmunology 4 e1019978
research 
paper TUMIMM Epigenetic modulation CTLA4 antitumor immunity TS/A
Delli Castelli et al. 2015
Sensitive MRI detection of internalized 
T<inf>1</inf>contrast agents using magnetization transfer 
contrast NMR Biomed 28 1663 1670
research 
paper IMAGING magnetic resonance MTC in vivo imaging TS/A
Di Gregorio et al. 2015
An MRI Method to Map Tumor Hypoxia Using Red Blood 
Cells Loaded with a pO<inf>2</inf>-Responsive Gd-Agent ACS Nano 9 8239 8248
research 
paper IMAGING magnetic resonance hypoxia in vivo imaging TS/A
Dolinsek et al. 2015
Endoglin silencing has significant antitumor effect on 
murine mammary adenocarcinoma mediated by vascular 
targeted effect Curr Gene Ther 15 228 244
research 
paper GT gene silencing endoglin angiogenesis TS/A 2H11
Mazzocco et al. 2015
Autologous cellular vaccine overcomes cancer 
immunoediting in a mouse model of myeloma Immunology 146 33 49 citation
Rizzitelli et al. 2015
Sonosensitive theranostic liposomes for preclinical in vivo 
MRI-guided visualization of doxorubicin release stimulated 
by pulsed low intensity non-focused ultrasound J Control Release 202 21 30
research 
paper IMAGING magnetic resonance lipid-based system targeting TS/A
Stimac et al. 2015
Gene electrotransfer of plasmid with tissue specific 
promoter encoding shRNA against endoglin exerts 
antitumor efficacy against murine TS/A tumors by vascular 
targeted effects PLoS ONE 10 e0124913
research 
paper GT gene silencing endoglin angiogenesis TS/A
B16F1, 
B16F10, 2H11
Vannucci et al. 2015
In vivo targeting of cutaneous melanoma using an 
melanoma stimulating hormone-engineered human 
protein cage with fluorophore and magnetic resonance 
imaging tracers J Biomed Nanotechnol 11 81 92
research 
paper IMAGING magnetic resonance nanoparticles drug delivery TS/A
Cottone et al. 2016
Leukocytes recruited by tumor-derived HMGB1 sustain 
peritoneal carcinomatosis Oncoimmunology 5 e1122860
control 
model BIOLMET/GT
inflammatory 
leukocytes HMGB1 growth inhibition TS/A
MC-38, CT26, 
C26, RMA
Falls et al. 2016 Murine tumor models for oncolytic rhabdo-virotherapy ILAR Journal 57 73 85 review
Karageorgis et al. 2016
An MRI-based classification scheme
to predict passive access of 5 to
50-nm large nanoparticles to
tumors Sci Rep 6 21417
research 
paper IMAGING magnetic resonance nanoparticles targeting TS/A-pc
Longo et al. 2016
In Vivo Imaging of Tumor Metabolism and Acidosis by 
Combining PET and MRI-CEST pH Imaging Cancer Res 76 6463 6470
research 
paper IMAGING magnetic resonance PET tumor metabolism TS/A
Longo et al. 2016
In Vitro and In Vivo Assessment of Nonionic Iodinated 
Radiographic Molecules as Chemical Exchange Saturation 
Transfer Magnetic Resonance Imaging Tumor Perfusion 
Agents Invest Radiol 51 155 162
research 
paper IMAGING magnetic resonance CEST in vivo imaging TS/A
2A B C D E F G H I J K L M N
Authors Year Title Source title Volume Page start Page end Type of study Category Keyword 1 Keyword 2 Keyword 3 TS/A cell variant 
Other murine cell 
lines
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
Maru 2016 Whole-Body Matter Inflamm Metast 12 1 505 review
Prunier et al. 2016
LIM kinase inhibitor Pyr1 reduces the growth and 
metastatic load of breast cancers Cancer Res 76 3541 3552
research 
paper BIOLMET
LIM Kinase Inhibitor 
Pyr1 taxan metastasis TS/A MEF
Riabov et al. 2016
Stabilin-1 is expressed in human breast cancer and 
supports tumor growth in mammary adenocarcinoma 
mouse model Oncotarget 7 31097 31110
research 
paper BIOLMET TAM stabilin1 growth inhibition TS/A
Rizzitelli et al. 2016
The release of Doxorubicin from liposomes monitored by 
MRI and triggered by a combination of US stimuli led to a 
complete tumor regression in a breast cancer mouse model J Control Release 230 57 63
research 
paper PHARM magnetic resonance doxorubicin growth inhibition TS/A
Sandoval et al. 2016
Standardized Extract from Caesalpinia spinosa is Cytotoxic 
over Cancer Stem Cells and Enhance Anticancer Activity of 
Doxorubicin Am J Chinese Med 44 1693 1717
research 
paper PHARM combination therapy doxorubicin chinese medicine TS/A B16, 4T1
Stimac et al. 2016 Tumor radiosensitization by gene therapy against endoglin Cancer Gene Ther 23 214 220
research 
paper GT gene silencing endoglin angiogenesis TS/A
Anemone et al. 2017
In vivo evaluation of tumour acidosis for assessing the early 
metabolic response and onset of resistance to 
dichloroacetate by using magnetic resonance 
pHdichloroacetate by using magnetic resonance pH 
imaging Int J Oncol 51 498 506
research 
paper IMAGING magnetic resonance glycolytic phenotype tumor metabolism TS/A
Anemone et al. 2017
MRI-CEST assessment of tumour perfusion using X-ray 
iodinated agents: comparison with a conventional Gd-
based agent Eur Radiol 27 2170 2179
research 
paper IMAGING magnetic resonance CEST tumor perfusion TS/A 4T1
Cavallari et al. 2017
13C MR Hyperpolarization of Lactate by Using 
ParaHydrogen and Metabolic Transformation in Vitro Chem-Eur J 23 1200 1204
research 
paper IMAGING
metabolic 
transformation ParaHydrogen tumor metabolism TS/A
Fuchs et al. 2017
A combinatorial alpha-beta T cell receptor expressed by 
macrophages in the tumor microenvironment Immunobiology 222 39 44
research 
paper TUMIMM TAM TCRalpha/beta antitumor immunity TS/A
Germano et al. 2017
Inactivation of DNA repair triggers neoantigen generation 
and impairs tumour growth Nature 552 1 5
research 
paper TUMIMM/GT neoantigens DNA repair CRISPR TS/A
CT26, MC38, 
PDAC
Hernández et al. 2017
A cytotoxic Petiveria alliacea dry extract induces ATP 
depletion and decreases β-F1-ATPase expression in breast 
cancer cells and promotes survival in tumor-bearing mice Braz J Pharmacogn 27 306 314
research 
paper PHARM tumor metabolism
american traditional 
medicine growth inhibition TS/A 4T1, 3T3
Kurena et al. 2017
Magnetic nanoparticles for efficient cell transduction with 
SemlikiForest virus J Virol Meth 245 28 34
research 
paper GT magnetofection
Semliki Forest viral 
vectors in vitro gene therapy TS/A 
Longo et al. 2017
EXCI-CEST: Exploiting pharmaceutical excipients as MRI-
CEST contrast agents for tumor imaging Int J Pharm 525 275 281
research 
paper IMAGING magnetic resonance CEST excipients TS/A B16-F10
Rong et al. 2017
Identifying tumor promoting genomic alterations in 
tumorassociated fibroblasts via retrovirus-insertional 
mutagenesis Oncotarget 8 97231 97245
research 
paper BIOLMET TAF insertional mutagenesis tumor progression TS/A
CT26, J558LFB-
61, MCA-205
Vanpouille-Box et al. 2017
DNA exonuclease Trex1 regulates radiotherapy-induced 
tumour immunogenicity Nat Commun 8 15618
research 
paper TUMIMM radiotherapy abscopal effect Trex1 TS/A 4T1, MCA38
Wang et al. 2017
Mammary adipocytes stimulate breast cancer invasion 
through metabolic remodeling of tumor cells JCI Insight 2 e87489
research 
paper BIOLMET mammary adipocytes microenvironment metastasis TS/A
Yang et al. 2017
Immunocompetent mouse allograft models for 
development of therapies to target breast cancer 
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